



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2020

Healthcare recommendations for Joubert syndrome

Bachmann-Gagescu, Ruxandra ; Dempsey, Jennifer C ; Bulgheroni, Sara ; Chen, Maida L ; D'Arrigo, Stefano ; Glass, Ian A ; Heller, Theo ; Héon, Elise ; Hildebrandt, Friedhelm ; Joshi, Nirmal ; Knutzen, Dana ; Kroes, Hester Y ; Mack, Stephen H ; Nuovo, Sara ; Parisi, Melissa A ; Snow, Joseph ; Summers, Angela C ; Symons, Jordan M ; Zein, Wadih M ; Boltshauser, Eugen ; Sayer, John A ; Gunay-Aygun, Meral ; Valente, Enza Maria ; Doherty, Dan

Abstract: Joubert syndrome (JS) is a recessive neurodevelopmental disorder defined by a characteristic cerebellar and brainstem malformation recognizable on axial brain magnetic resonance imaging as the "Molar Tooth Sign". Although defined by the neurological features, JS is associated with clinical features affecting many other organ systems, particularly progressive involvement of the retina, kidney, and liver. JS is a rare condition; therefore, many affected individuals may not have easy access to subspecialty providers familiar with JS (e.g., geneticists, neurologists, developmental pediatricians, ophthalmologists, nephrologists, hepatologists, psychiatrists, therapists, and educators). Expert recommendations can enable practitioners of all types to provide quality care to individuals with JS and know when to refer for subspecialty care. This need will only increase as precision treatments targeting specific genetic causes of JS emerge. The goal of these recommendations is to provide a resource for general practitioners, subspecialists, and families to maximize the health of individuals with JS throughout the lifespan.

DOI: <https://doi.org/10.1002/ajmg.a.61399>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-179355>

Journal Article

Accepted Version

Originally published at:

Bachmann-Gagescu, Ruxandra; Dempsey, Jennifer C; Bulgheroni, Sara; Chen, Maida L; D'Arrigo, Stefano; Glass, Ian A; Heller, Theo; Héon, Elise; Hildebrandt, Friedhelm; Joshi, Nirmal; Knutzen, Dana; Kroes, Hester Y; Mack, Stephen H; Nuovo, Sara; Parisi, Melissa A; Snow, Joseph; Summers, Angela C; Symons, Jordan M; Zein, Wadih M; Boltshauser, Eugen; Sayer, John A; Gunay-Aygun, Meral; Valente, Enza Maria; Doherty, Dan (2020). Healthcare recommendations for Joubert syndrome. *American Journal of Medical Genetics. Part A*, 182(1):229-249.

DOI: <https://doi.org/10.1002/ajmg.a.61399>

Healthcare recommendations for Joubert syndrome

Authors

Ruxandra Bachmann-Gagescu^{1, 2}, Jennifer C. Dempsey³, Sara Bulgheroni⁴, Maida Lynn Chen^{3, 5}, Stefano D'Arrigo⁴, Ian A. Glass³, Theo Heller⁶, Elise Héon^{7, 8}, Friedhelm Hildebrandt^{9, 10}, Nirmal Joshi^{11, 12}, Dana Knutzen^{13, 14}, Hester Y. Kroes¹⁵, Stephen H. Mack¹⁶, Sara Nuovo^{17, 18}, Melissa A. Parisi¹⁹, Joseph Snow²⁰, Angela C. Summers^{20, 21}, Jordan M. Symons^{3, 22}, Wadih M. Zein²³, Eugen Boltshauser²⁴, John A. Sayer^{25, 26, 27}, Meral Gunay-Aygun^{28, 29}, Enza Maria Valente^{17, 30}, Dan Doherty³¹

Author Affiliations

¹ Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland

² Institute of Medical Genetics, University of Zurich, Schlieren, Switzerland

³ Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA

⁴ Developmental Neurology Division, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

⁵ Division of Pulmonary and Sleep Medicine, Seattle Children's Hospital, Seattle, Washington, USA

⁶ Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA

⁷ Hospital for Sick Children, Department of Surgery, Toronto, Ontario, Canada

⁸ University of Toronto, Department of Ophthalmology and Vision Science, Toronto, Ontario, Canada

⁹ Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA

¹⁰ Division of Nephrology, Boston Children's Hospital, Massachusetts, USA

¹¹ Department of Anesthesia, Deaconess Hospital, Evansville, Indiana, USA

¹² Anesthesia Dynamics, LLC, Evansville, Indiana, USA

¹³ Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas, USA

¹⁴ The Children's Hospital of San Antonio, San Antonio, Texas, USA

¹⁵ Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

¹⁶ Joubert Syndrome Foundation, Grayslake, Illinois, USA

¹⁷ Neurogenetics Lab, IRCCS Santa Lucia Foundation, Rome, Italy

¹⁸ Department of Medicine and Surgery, University of Salerno, Salerno, Italy

¹⁹ Intellectual and Developmental Disabilities Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA

²⁰ Office of the Clinical Director, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA

²¹ Department of Psychology, Fordham University, Bronx, New York, USA

²² Division of Nephrology, Seattle Children's Hospital, Seattle, Washington, USA

²³ Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health
Bethesda, Maryland, USA

²⁴ Department of Pediatric Neurology (emeritus), Children's University Hospital, Zürich, Switzerland

²⁵ Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

²⁶ Renal Services, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

²⁷ NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK

²⁸ Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA

²⁹ Johns Hopkins University School of Medicine, Department of Pediatrics and McKusick-Nathans Institute of Genetic Medicine, Baltimore, Maryland, USA

³⁰ Department of Molecular Medicine, University of Pavia, Pavia, Italy

³¹ Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA

Grant Numbers

WMZ- NIH Intramural Research Program

FH- NIH 068306

JAS- Northern Counties Kidney Research Fund, Kidney Research UK, Medical Research Council MR/M012212/1

EMV- European Research Council starting grant 260888, Italian Ministry of Health NET-2013-02356160, Pierfranco and Luisa Mariana Foundation PADAPORT project

DD- NICHD U54HD083091 sub-project 6849, NINDS R01NS064077

Conflict of Interest

FH is a cofounder and SAB member of Goldfinch-Bio.

Abstract

Joubert syndrome (JS) is a recessive neurodevelopmental disorder defined by a characteristic cerebellar and brainstem malformation recognizable on axial brain MRI as the “Molar Tooth Sign” (MTS). Although defined by the neurological features, JS is associated with clinical features affecting many other organ systems, particularly progressive involvement of the retina, kidney and liver. JS is a rare condition; therefore, many affected individuals may not have easy access to subspecialty providers familiar with JS (e.g. geneticists, neurologists, developmental pediatricians, ophthalmologists, nephrologists, hepatologists, psychiatrists, therapists and educators). Expert recommendations can enable practitioners of all types to provide quality care to individuals with JS and know when to refer for subspecialty care. This need will only increase as precision treatments targeting specific genetic causes of JS emerge. The goal of these recommendations is to provide a resource for general practitioners, subspecialists, and families to maximize the health of individuals with JS throughout the lifespan.

Keywords

Joubert syndrome, ciliopathy, treatment, retina, kidney, liver

Introduction

Joubert syndrome (JS, MIM PS213300) is a recessive neurodevelopmental disorder defined by a characteristic cerebellar and brainstem malformation recognizable on axial brain MRI as the “Molar Tooth Sign” (MTS).[Joubert and others 1969; Maria and others 1997] This appearance results from a combination of abnormalities: cerebellar vermis aplasia/hypoplasia, thick and horizontally-oriented superior cerebellar peduncles, and often, a deep interpeduncular fossa. Clinically, individuals with JS typically present as infants with hypotonia, abnormal eye movements, respiratory control disturbances, and as children or adults, ataxia and/or cognitive impairment.[Doherty 2009; Parisi and Glass 1993; Romani and others 2013] In addition to these core features, the majority of individuals with JS also have involvement of other body systems including the eye, kidney, liver and skeleton.[Bachmann-Gagescu and others 2015a] Therefore, rather than a purely neurological condition, JS is a multisystem disorder in which several of the additional features may be progressive, thereby substantially complicating medical management. While the diagnosis is often made initially in the setting of a neurology, genetics, or developmental pediatrics clinic, the frequent involvement of other organ systems means that monitoring for complications is required, with referral to the corresponding subspecialists when specific organ involvement is suspected. The purpose of this review is to provide management recommendations to minimize medical complications and maximize quality of life for individuals with JS. We hope to address a broad audience including families, primary care providers and subspecialists, since JS is rare, and few providers have experience with more than a handful of affected individuals.

Given that JS is rare (prevalence estimated at 1/55,000-1/200,000),[Kroes and others 2007; Nuovo and others 2019; Parisi and Glass 1993] the present recommendations represent a consensus of expert opinion, based on observed outcomes in JS and extrapolation from more common disorders. In general, these recommendations focus on the goals of monitoring and treatment without being directive as to which medical specialists or techniques are most appropriate, since the availability of subspecialists and specific medical technologies varies widely. Some of the evaluations and treatments mentioned in these recommendations are not available in all healthcare settings, so we try to provide options that will work in a variety of healthcare environments.

JS is part of the larger group of disorders called ciliopathies, based on shared genetic causes and overlapping phenotypes related to dysfunction of the primary cilium.[Reiter and Leroux 2017] Therefore, some of the present recommendations may be useful for individuals with other related ciliopathies, in particular nephronophthisis (MIM PS256100), Leber congenital amaurosis (MIM PS204000), Senior-Løken syndrome (MIM PS266900), acrocallosal syndrome (MIM 200990), oral-facial-digital syndromes (MIM PS311200), or MORM (“Mental retardation, truncal Obesity, Retinal dystrophy, and Micropenis”) syndrome (MIM 610156).

Methods

We reviewed the medical literature from the time of the initial description of JS[Joubert and others 1969] to the present. The estimated prevalence of features is based on a cohort of >600 individuals with JS (“University of Washington (UW) cohort”),[Bachmann-Gagescu and others] an overlapping series of 100 individuals with JS evaluated through the intramural National Institutes of Health research protocol “Clinical and Molecular Investigations Into Ciliopathies” (ClinicalTrials.gov, NCT00068224 – “The NIH cohort”), and the literature. The NIH cohort appears enriched for liver involvement and coloboma compared to other cohorts; this may be due to differences in enrollment, assessment for clinical features, or other factors. No trials of monitoring strategies or treatments have been performed in individuals with JS; therefore, the recommendations below are based on professional judgment of the authors and extrapolation from paradigms for similar issues in other populations.

Clinical diagnosis of JS: diagnostic criteria

For the purpose of this paper, the diagnosis of JS requires the presence of the MTS on axial brain MRI (or CT) of optimal quality, including thin sections through the posterior fossa (Fig 1). Despite widespread publication of the imaging features of JS, the diagnosis is initially missed in a substantial number of individuals, so review by an experienced pediatric neuroradiologist, neurologist, or other practitioner with specific knowledge of JS can be critical. In some individuals, the features of the MTS are not captured in a single image and must be reconstructed from multiple images. Superior cerebellar dysplasia on axial view (Fig 1B), thick, horizontally-oriented superior cerebellar peduncles (Fig 1C and 1E) and elevated roof of the 4th ventricle (Fig 1D) on sagittal views, as well as a cleft vermis on coronal view (Fig F) can also be helpful. Diffusion tensor imaging has been used to highlight deficient midline crossing (decussation) of the superior cerebellar peduncle tracts near the red nucleus, which appears to be present in the majority of individuals.[Poretti and others 2007; Widjaja and others 2006] Multiple additional brain anomalies have been described in individuals with JS as described in the “Neurodevelopmental” section below.

Not surprisingly, individuals with a subtle MTS or without the full combination of imaging features that result in the MTS can still have pathogenic variants in genes associated with JS (unpublished observations and [Enokizono and others 2017; Parisi and others 2004; Shaheen and others 2016]). The risk of retinal, kidney, and liver involvement in individuals with partial features of JS is unknown.

In the absence of an appropriate brain MRI, a provisional diagnosis of JS can be made based on classic features of hypotonia, developmental delay, ataxia, ocular motor apraxia and respiratory rhythm disturbances (tachypnea and/or apnea), along with cerebellar vermis hypoplasia by ultrasound or computed tomography imaging. JS is not associated with an easily recognizable facial appearance; however, some distinctive facial features, such as a prominent lower jaw, are shared by many individuals and can be supportive of the diagnosis.[Braddock and others 2007; Maria and others 1999]

Prenatally, the possibility of JS can be raised by cerebellar vermis hypoplasia detected on routine ultrasound. Fetal MRI may be helpful in further delineating anomalies identified by ultrasound;[Aslan and others 2002; Doherty and others 2005; Fluss and others 2006; Saleem and Zaki 2010] however, the typical MTS is often not detected prenatally (unpublished observations). In pregnant women with a prior affected child, the finding of definite vermis hypoplasia on ultrasound or MRI can be considered diagnostic. In the absence of a family history, the reliability of prenatal diagnosis by imaging is unknown; however, a combination of cerebellar vermis hypoplasia with other distinctive JS/ciliary features such as polydactyly, or enlarged, cystic, or echogenic kidneys may suggest a JS diagnosis even in the absence of a family history.

The differential diagnosis for JS includes other disorders with anomalies of the posterior fossa such as Dandy-Walker malformation, Poretti-Boltshauser syndrome (MIM 615960), and other conditions associated with ataxia and/or cerebellar vermis hypoplasia. Many children with JS are first given a diagnosis of ocular motor apraxia, or ataxic cerebral palsy before the MTS is identified. The differential diagnosis also includes genetically and phenotypically overlapping ciliopathies such as Meckel syndrome (MIM PS249000) which likely represents the severe end of a Joubert-Meckel spectrum, oral-facial-digital, acrocallosal, Mainzer-Saldino (MIM 266920), COACH (MIM 216360, Cerebellar vermis hypo/aplasia, Oligophrenia, Ataxia, ocular Coloboma, and Hepatic fibrosis), or hydroletharus (MIM PS236680) syndromes. For the purpose of this review, we include all individuals with the MTS under the umbrella of JS, even if they have other clinical features consistent with other diagnostic categories. This includes diagnostic categories such as Joubert Syndrome and Related Disorders (JSRD), cerebello-renal syndromes (CORS), as well as subtypes of JS defined by features outside the brain such as JS with renal involvement or JS with oral-facial-digital features.[Brancati and others 2010; Parisi and Glass 2006] In fact, only a minority of people with JS have isolated brain involvement. When individuals with JS have atypical clinical features (particularly in consanguineous families), the possibility of a second unrelated genetic disorder should be considered and additional genetic testing beyond known ciliopathy genes may be warranted.

Molecular diagnosis of JS

JS can be caused by pathogenic variants in >35 genes (Table 1). Biallelic pathogenic variants¹ in one of the known JS-associated genes can be identified in 50-92% of individuals with JS depending on the cohort, sequencing method and criteria for causal variants.[Bachmann-Gagescu and others 2015a; Shaheen and others 2016; Vilboux and others 2017a] In two overlapping cohorts, 5-6 genes (*AHI1*, *CC2D2A*, *CEP290*, *CPLANE1*, *KIAA0586*, and *TMEM67*) account for 40-70% of families.[Bachmann-Gagescu and others 2015a; Vilboux and others 2017a] Given this substantial genetic heterogeneity (i.e. multiple genetic causes for the same phenotype), and the fact that no single variant or gene predominates, the most time-efficient and economical means of molecular diagnosis can be achieved through next-generation sequencing (NGS) of either a panel of known JS genes, an exome (protein coding regions), or a genome (all DNA that can be sequenced). These latter methods have the advantage of requiring no specific set-up or updating as additional genes are associated with the phenotype.

For several ethnic groups, initial sequencing for common founder variants may be logical. Specifically, the *TMEM216* p.R73L variant is common in individuals of Ashkenazi origin and *TMEM237* p.R18* is common in Hutterites.[Edvardson and others 2010; Huang and others 2011] In French Canadians, several recurring *CPLANE1*, *CC2D2A*, and *TMEM231* pathogenic variants have been identified, so genetic testing can be prioritized by ethnic background;[Srour and others 2012a; Srour and others 2012b] however, these associations are not sufficient to enable reliable prediction of the genetic cause based on the phenotypes, so sequencing of all JS-associated genes by NGS is often preferable.

The motivation underlying the identification of a molecular diagnosis, besides confirming the clinical diagnosis of JS and providing information regarding recurrence risk/family planning, lies in the known gene-phenotype correlations.[Bachmann-Gagescu and others 2015a; Brancati and others 2007; Brancati and others 2009; Doherty and others 2010; Vilboux and others 2017a] Indeed, these correlations can be used to adjust the frequency of monitoring for progressive features such as retinal dystrophy and kidney disease, as described in Tables 3 and 4 and the “Adjusted follow-up recommendations based on gene-phenotype associations” section below. Furthermore, it may be prudent to avoid nephrotoxic medications in individuals at the highest risk for kidney involvement, without unnecessarily restricting these medications in those at low risk. In the future, the genetic diagnosis may determine eligibility for specific therapies such as gene-specific medications, antisense oligonucleotide treatments, or gene therapy (see “Precision treatments” section below).

¹or hemizygous pathogenic *OFD1* variants

System-by-system review of potential clinical issues

Neurodevelopmental: Essentially all individuals with JS experience hypotonia and motor delays during infancy and early childhood, usually evolving to ataxia as they get older. Abnormal eye movements and abnormal respiratory control are also seen in most, but may be subtle. Cognition is impaired in most, although a minority of individuals have IQs in the normal range.[Bulgheroni and others 2016; Fennell and others 1999; Gitten and others 1998; Summers and others 2017] In general, adaptive function correlates with cognitive function.[Bulgheroni and others 2016; Summers and others 2017] However, slowed processing speed is common, so neuropsychological and school evaluations should examine both Full Scale Intelligence Quotient (FSIQ) and the Generalized Ability Index (GAI) or similar measures to help contextualize the individual’s intellectual abilities. Because the GAI relies less on speeded and motor tasks, a more accurate representation of cognitive abilities may be ascertained from this or similar scores than from a traditional measure of FSIQ. These studies must be interpreted with caution due to potential ascertainment biases (for more or less severely affected individuals) and difficulties measuring IQ in the presence of significant motor, communication, and visual impairments. Regardless, the range of neurodevelopmental outcome is very broad. Speech production is impacted out of proportion to language comprehension due to oral motor apraxia.[Braddock and others 2006] Periodic developmental monitoring is required, as well as standard therapies (physical, occupational, speech/language) and educational interventions to build on areas of strength and target areas of weakness. No specific types of therapy have been shown to be more or less effective in this population. Motor issues, particularly the ataxia and the ocular motor apraxia, appear to improve as children mature. Most children with JS eventually walk independently, although a subset require wheelchairs for some or all mobility.

Multiple additional brain anomalies have been described in individuals with JS,[Bachmann-Gagescu and others 2015a; Poretti and others 2017] most commonly cerebellar hemisphere enlargement, malrotation of the hippocampi, ventriculomegaly, dysgenesis of the corpus callosum, polymicrogyria, heterotopia and occipital encephalocele. While vermis size and abnormal EEG have been associated with severity of neurodevelopmental outcome,[Poretti and others 2017; Summers and others 2017] no imaging or clinical features can reliably predict neurodevelopmental outcome in a given individual. It is suspected that additional major brain malformations, multi-organ involvement, chronic mechanical ventilation, and sensory impairments are associated with higher risk of more severely abnormal neurodevelopmental outcomes.

Ptosis, strabismus, and abnormal eye movements including nystagmus and ocular motor apraxia are neurologically-based vision issues which may be present to some degree in all individuals.[Brooks

and others 2018; Khan and others 2008; Sturm and others 2010; Weiss and others 2009] In particular, ocular motor apraxia (head thrusting to shift gaze) is characteristic of JS, although it can be seen in other conditions. While visual acuity is often normal and eye movements tend to improve with time, abnormal smooth pursuit and saccades likely result in some degree of functional visual impairment, particularly when objects or the individual's head are moving.

Seizures have been described in a number of individuals with JS (minimum prevalence 10%)[Bachmann-Gagescu and others 2015a] and must be specifically sought out during recording of the medical history. No single seizure type appears to dominate and there is no evidence to suggest that anti-epileptic treatments should differ from those administered to individuals with non-JS associated epilepsy. While ventriculomegaly is noted relatively frequently on MRIs of individuals with JS, true hydrocephalus requiring treatment is rare. However, since this complication is treatable and can have adverse consequences if left untreated, regular monitoring by measurement of head circumference is recommended in young children. A small subset of individuals has dystonic movements (often facial grimacing) and bite their tongues and cheeks. This is a particularly difficult problem, and no successful treatments have been published.[Farmer and others 2006] Apparent temperature regulation problems have also been reported including episodic unexplained fevers (resulting in infectious disease evaluations) and heat intolerance associated with decreased function during hot weather (unpublished observations). The prevalence of these features is unknown.

A variety of behavioral and psychiatric issues have been reported in individuals with JS including tantrums, self-injury, autism, depression, anxiety, and auditory hallucinations.[Bachmann-Gagescu and others 2015a; Bulgheroni and others 2016; Fennell and others 1999; Summers and others 2017] These issues can have an enormous impact on the quality of life for people with JS and their families. Parent-reported Child Behavior Checklist (CBCL) data were available for 45/76 individuals who received a neuropsychological evaluation at NIH. Scores were elevated across all scales except for the externalizing behaviors summary scale (e.g., aggression and tantrums), indicating increased rates of behavioral issues compared to the general population.[Summers and others 2017]

Data on psychiatric diagnoses in JS is exceedingly scarce; however, in an Italian cohort of 54 directly-evaluated individuals, 39% were reported to have behavioral issues, and 7% were diagnosed with psychiatric conditions (two with oppositional defiant disorder and two with bipolar disorder).[Bulgheroni and others 2016] Within the NIH sample, individuals with JS took psychiatric medications at a higher rate than rates reported in typically developing children and adults; however, the rate of psychiatric medications in individuals with JS appears to be lower than rates reported in other populations with intellectual and developmental disabilities, more generally.[Howie and others 2014; Jonas and others 2013] Furthermore, within the NIH sample, those with JS who had a greater degree of intellectual disability also appear to receive more psychiatric medications.[Summers and others 2017]

Circadian rhythm abnormalities and behavioral sleep disturbances have been reported but not formally assessed.[Kamdar and others 2011] Additional research is needed to fully delineate the spectrum of neurobehavioral and psychiatric issues. Similar to neurobehavioral and psychiatric issues in other populations affected by neurodevelopmental conditions, these issues are treated with behavioral interventions appropriate for the individual (e.g. parent-child interaction therapy, applied behavioral analysis, cognitive-behavioral therapy and other therapies), counseling, and medications when necessary. Optimizing the treatment of any medical issues is an essential component of neurobehavioral and psychiatric care, since pain and illness can exacerbate behavioral issues.

Eyes and vision: In addition to the neurologically-based eye issues mentioned above, visual function may be impacted by coloboma, retinal dysfunction, optic atrophy, and refractive error. Coloboma results from abnormal closure of the optic cup during development, and usually affects the retina or optic nerve, but rarely the iris in JS. Typically, colobomata involving the macula or optic nerve cause visual impairment. Retinal dysfunction in JS is likely the direct result of problems with the photoreceptor outer segment, which is a highly modified cilium. Retinal dystrophy can be apparent at birth or lead to progressive decline in vision due to degenerating photoreceptors. Retinal abnormalities can be confirmed by an ERG (ElectroRetinoGram) which would show decreased electrical responses in the retina, or OCT (Optical Coherence Tomography) which would show abnormal layering of the retina with atrophy. Although poorly detailed in the literature, the retinal dystrophy can range from congenital retinal blindness diagnosed in infancy (Leber Congenital Amaurosis) to a slowly progressive degeneration that can result in nyctalopia (night blindness) or eventual blindness after the second decade.[Coene and others 2009] Retinal involvement (defined as abnormal ERG, abnormal OCT, and/or abnormal retinal pigment with visual impairment) was present in 30% of individuals in the UW cohort, while coloboma was seen in ~17%.[Bachmann-Gagescu and others 2015a] In the overlapping, directly-evaluated NIH cohort, 24% had retinal dystrophy, 28% had coloboma, and 9% had optic nerve atrophy.[Brooks and others 2018] Some genetic causes (e.g. *CEP290* and *AHI1* dysfunction) are more likely to be associated with more severe retinal degeneration than others (e.g. *INPP5E*, *MKS1* and *NPHP1* dysfunction).

While ptosis is common, it rarely obstructs vision enough to require treatment. Significant refractive error (both myopia and hyperopia) have also been reported and can be treated with corrective spectacles. Patients with significant (“high”) myopia should be monitored for retinal detachment by yearly dilated retinal examination. Strabismus (ocular misalignment) is also common and may lead to amblyopia (“lazy eye”), a preventable form of vision loss if caught early enough. Surgical treatment of strabismus should be approached with caution, as the strabismus is often variable in JS.[Brooks and others 2018] Given the potential overlap with Poretti-Boltshauser syndrome,[Aldinger and others 2014; Poretti and others 2014] high myopia should prompt a re-review of the MRI for cerebellar hemisphere dysplasia, cerebellar cysts, and patchy increased T2/FLAIR signal in the cortical white matter, characteristic of Poretti-Boltshauser syndrome.

Loss of visual function may go unrecognized in individuals with cognitive impairment, further limiting their developmental potential and interaction with the world; therefore, it is important to assess for visual impairment early and provide supportive measures to affected individuals and their families as soon as possible. Interventions should aim at improving quality of life. Ideally, a baseline assessment for the issues described above would be performed by a pediatric ophthalmologist when JS is diagnosed or suspected. Regular follow-up ophthalmological evaluations are warranted for surveillance and treatment of the issues described above.

Kidney: Fibrocystic kidney disease develops in 25-30% of individuals, and frequently progresses to end-stage renal disease (ESRD).[Bachmann-Gagescu and others 2015a; Fleming and others 2017] Of the 29 individuals with kidney involvement in the NIH cohort, 31% had nephronophthisis, 35% had an overlap-phenotype of autosomal recessive polycystic kidney disease/nephronophthisis, 10% had a unilateral multicystic dysplastic kidney, and 24% had indeterminate-type cystic kidney disease.[Fleming and others 2017] Initially, individuals with nephronophthisis may display polyuria and polydipsia. Subsets of individuals can present with a kidney phenotype similar to autosomal recessive polycystic kidney disease with prenatal onset of enlarged kidneys and early onset

hypertension.[Fleming and others 2017; Gunay-Aygun and others 2009] The minimal prevalence for ESRD in the UW cohort was 5.1% (n=30/586, 24 received a kidney transplant),[Bachmann-Gagescu and others 2015a] while in an overlapping cohort of individuals evaluated directly, the prevalence was 30% (n=13/97, 11 received a kidney transplant).[Fleming and others 2017] Kidney failure appears to be the leading cause of death in JS individuals over 1 year of age, but ESRD has also been observed in infants.[Dempsey and others 2017] Anemia is a common clinical finding in those with nephronophthisis, often noted to be more severe than expected given the level of kidney dysfunction. Poor weight gain or feeding issues can also be associated with kidney dysfunction. While no specific treatments to cure or slow the progression of nephronophthisis are currently available, the goals of early diagnosis are to maintain quality of life and limit complications of chronic kidney disease (CKD) including anemia, bone mineral loss, malnutrition and poor somatic growth. Although not systematically evaluated, the risk posed by nephrotoxic medications such as aminoglycosides may be increased, so these medications should be avoided when possible. Likewise, non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution.

Individuals should be monitored for signs and symptoms of CKD including at least yearly blood pressure measurements and laboratory testing for serum electrolytes, calcium, phosphorus, creatinine, blood urea nitrogen (BUN), and blood count with hematocrit/hemoglobin. Urine concentrating ability may be an effective means of monitoring for CKD in JS. In one study of 93 individuals with JS, CKD was predicted in >75% with urine osmolality <600 mOsm/kg, and CKD was significantly increased in patients with an early diagnosis of isolated urinary concentrating defect.[Nuovo and others 2018] Estimated glomerular filtration rate in children [Schwartz and others 2012] and adults [Levey and others 2009] should be monitored by serum creatinine or creatinine and cystatin C when available, since cystatin C may be more accurate in patients with limited muscle mass.

Kidney ultrasound may be useful for identifying kidney involvement (altered size, increased echogenicity, loss of corticomedullary differentiation, or overt cysts); however, the value of periodic kidney ultrasounds for follow-up is unclear, since ultrasonographic appearance does not reflect kidney function, which guides medical management. Therefore, we recommend a kidney ultrasound at diagnosis to evaluate for genitourinary malformations and establish the presence or absence of kidney involvement. It is reasonable to get a second ultrasound during adolescence, and in addition, kidneys may be evaluated periodically during the abdominal ultrasounds performed to follow spleen size (see below). Follow-up for kidney involvement should rely primarily on history, physical examination and blood and urine tests.

Liver: Many individuals with JS have chronically elevated transaminases and GGT (Gamma-glutamyl transferase);[Bachmann-Gagescu and others 2015a; Strongin and others 2018; Vilboux and others 2017a] however, only a small subset of individuals with JS develop hepatic fibrosis severe enough to result in portal hypertension. Nonetheless, variceal bleeding can be a serious or even fatal complication. In the UW cohort, at least 13 individuals had portal hypertension indicating a minimal prevalence of 2% (4 had splenomegaly, 2 had esophageal varices, 6 required a porto-systemic shunt and 3 required liver transplantation). In the overlapping NIH cohort, 41% had elevated liver enzymes and 13% had probable or definite portal hypertension.[Strongin and others 2018] Potential treatments for portal hypertension include banding or sclerosis of esophageal varices to prevent bleeding, porto-systemic shunt placement to reduce portal pressure, and liver transplantation.

The goal of monitoring is to identify and treat portal hypertension to avoid variceal bleeding. Preferred monitoring includes serial platelet measurements looking for a decreasing trend, and serial abdominal ultrasounds (every 2-3 years) looking for abnormal increase in spleen size.[Gunay-Aygun and others 2013] Chronically elevated transaminases and GGT may indicate increased risk for portal hypertension.[Strongin and others 2018] Possible gastrointestinal bleeding in individuals with JS must be evaluated urgently, with strong consideration of endoscopy to evaluate for esophageal varices. Treatment for varices is not JS-specific and can involve sclerotherapy, banding, porto-systemic shunt placement, and liver transplantation may be needed in rare cases.

Differing from cirrhosis, the liver disease in JS and other ciliopathies (congenital hepatic fibrosis) does not impair the synthetic function of the liver;[Gunay-Aygun and others 1993] therefore, individuals with JS do not appear to be at higher risk for complications from hepatotoxic medications, unless they have other risk factors such as hepatitis or liver transplantation. All children with JS should receive vaccinations against hepatitis A and B. Liver biopsy is generally not indicated in individuals with confirmed JS, since the results do not change treatment which is focused on the sequelae of portal hypertension. Liver cysts and enlarged intrahepatic bile ducts (e.g. Caroli syndrome), observed in other ciliopathies, have not been seen in JS, so the risk for cholangitis does not appear to be increased.

Other gastrointestinal complications: A subset of individuals has feeding difficulties, likely due to bulbar dysfunction. Aspiration is also frequently reported. Individuals with poor weight gain or recurrent infections should be evaluated for swallow dysfunction and aspiration. Treatment can include feeding therapy from a speech or occupational therapist, and short- or long-term tube feedings may be required. In a large cohort, the minimal prevalence of tube feedings was 10% (8% G-tube and 2% nasogastric tube).[Bachmann-Gagescu and others 2015a] Drooling can also be a chronic issue associated with skin breakdown and social difficulties. Treatments can involve positioning, oral-motor therapy, oral medications, and injected botulinum toxin. While a few individuals have been reported with JS and Hirschsprung disease (manifested by intractable constipation), this appears to be a rare or chance association.[Brancati and others 2010; Ozyurek and others 2008] On the other hand, constipation unrelated to Hirschsprung disease is common in JS. Management of constipation should therefore first rely on medical measures, and in case of intractable symptoms, evaluation for Hirschsprung disease and other causes should be initiated.

Respiratory: Abnormal respiratory control has been clearly documented in infants and children with JS by polygraphic recordings, characterized by episodes of apnea, tachypnea and/or hyperpnea.[Boltshauser and others 1981; Joubert and others 1969] Abnormal respiratory patterns and sleep behaviors have also been described more recently by caregiver report,[Kamdar and others 2011] and compared to their siblings (unpublished). Although not explicitly documented in the literature, our experience indicates that the respiratory control abnormalities improve with age in most patients. Nonetheless, in some individuals, respiratory control abnormalities are severe enough to warrant chronic ventilation.[Mercado and others 1991] In a retrospective study of individuals with JS who had died, apnea and respiratory failure were the leading causes of death in children under 1 year of age but were also the cause of death in multiple individuals older than 1 year of age.[Dempsey and others 2017] Older children and adults with JS have an increased risk of central and obstructive sleep-disordered breathing compared to population data, especially if they are obese.[Andermann and others 1999; Wolfe and others 2010] Sleep-disordered breathing can also cause or worsen neurobehavioral issues,[Witmans and Young 2011] and if untreated, lead to pulmonary hypertension. No systematic data exist to guide monitoring, but at a minimum, surveillance should include yearly

history and examination for sleep and breathing disturbances. Capillary blood gas and electrolytes in younger children and those with obesity can help identify hypoventilation. Sleep medicine consultation or polysomnography should be considered for symptomatic individuals. Rare individuals with JS additionally have restrictive lung disease due to co-existing skeletal dysplasia such as Jeune syndrome.[Halbritter and others 2013; Lehman and others 2010; Shaheen and others 2015; Tuz and others 2014] Several male individuals with hemizygous *OFD1* variants have been reported to have recurrent respiratory infections similar to individuals with primary ciliary dyskinesia (unpublished and [Budny and others 2006; Coene and others 2009]); however, additional research is required to determine whether individuals with JS are at increased risk for respiratory issues due to abnormal mucociliary clearance. Clinicians should consider evaluation for primary ciliary dyskinesia in individuals with JS and recurrent respiratory infections. Severely affected individuals are at risk for chronic respiratory failure and aspiration pneumonia.

Endocrine: Various endocrinological abnormalities are increased in individuals with JS, such as central diabetes insipidus, premature puberty, hypothyroidism, pituitary dysfunction, growth hormone deficiency, and/or panhypopituitarism, affecting together 4%.[Bachmann-Gagescu and others 2015a] An additional 1-2% have Type I diabetes mellitus, hypothyroidism, polycystic ovarian syndrome, and ovarian “failure” which may or may not be increased in JS. Short stature and growth hormone deficiency have also been reported;[Bachmann-Gagescu and others 2015a; Stephen and others 2017; Vilboux and others 2017b] therefore, we recommend closely monitoring for symptoms of hypothyroidism, dehydration or fluid overload, poor linear growth, and precocious or delayed pubertal development. As noted above, problems with linear growth or polyuria/urinary concentrating defects may also be related to kidney involvement.

Musculoskeletal: Similar to other individuals with hypotonia, those with JS have an increased risk for scoliosis which is present in at least 5% of individuals;[Bachmann-Gagescu and others 2015a] however, it rarely requires treatment. Monitoring for scoliosis by physical examination should be performed every 1-2 years until growth is complete. Referral to an orthopedic surgeon is indicated if the scoliosis may progress to the point that it causes restrictive respiratory disease, difficulty with upright posture, and/or pain. 15% of individuals have polydactyly[Bachmann-Gagescu and others 2015a] that can be left alone or surgically addressed, depending on the stability of the extra digits, difficulty fitting into shoes and gloves, and family preference. In a few families, skeletal dysplasia is present in addition to typical JS features, so that a mixed Joubert-Jeune syndrome phenotype is observed.[Bachmann-Gagescu and others 2015b; Halbritter and others 2013; Malicdan and others 2015; Tuz and others 2014]

Cardiovascular: Rare individuals with severe complex congenital heart disease have been reported [Karp and others 2012]; however, only 1-2% of individuals have congenital heart disease, including atrial septal defect, coarctation of the aorta, bicuspid aortic valve, and aortic stenosis.[Bachmann-Gagescu and others 2015a] Individuals with murmurs, cyanosis, poor perfusion, and other manifestations of possible congenital heart disease should be evaluated by a pediatric cardiologist. The utility of a screening echocardiogram has not been evaluated. In the United States, screening all newborns for congenital heart disease by physical examination and pulse oximetry is recommended as part of standard newborn screening programs.[Oster and others 2016]

Ear, nose and throat: A variety of oral manifestations including tongue hamartomas, additional frenulae (under the tongue and between the cheeks and gums), and cleft lip/palate have been reported, illustrating the phenotypic overlap between JS and oral-facial-digital syndrome(s).[Poretti

and others 2012; Thauvin-Robinet and others 2014] In a small cohort of 22 individuals with JS, conductive hearing loss was reported in 6 and mild sensorineural hearing loss was reported in 3, all of them older than 17 years of age.[Kroes and others 2010] In contrast, the prevalence of hearing loss in a larger cohort was 3%, which is still substantially higher than the 1-2/1000 population prevalence in children.[Bachmann-Gagescu and others 2015a; Fortnum and others 2001] No systematic data indicate that individuals with JS should be screened for hearing loss differently than other individuals; however, it is important to have a low threshold for audiology evaluation, since many forms of hearing loss are treatable, and even mild hearing loss can adversely affect speech/language development.

Sedation and anesthesia: Individuals with JS may require sedation for a variety of procedures, most commonly dental care. Given their known structural abnormalities of the brainstem, central respiratory control problems, airway hypotonia and swallow dysfunction, they should be considered high-risk for anesthesia. In at least 20 individuals reported in the literature, apnea is a common complication, sometimes requiring airway intervention such as intubation or mask airway.[Atalay and others 2016; Bhaskar and others 2013; Buntenbroich and Dullenkopf 2013a; Buntenbroich and Dullenkopf 2013b; Galante and others 2009; Habre and others 1997; Matthews 1989; Platis and others 2006; Sriganesh and others 2010; Sriganesh and others 2014; Vodopich and Gordon 2004] Some authors suggest avoiding sedatives known to be associated with central respiratory depression, and avoiding unnecessary conscious sedation for brief, uncomplicated procedures such as MRI when possible; however, insufficient evidence exists to provide specific guidelines for individuals with JS. To ensure timely and appropriate management of potential complications, interventions that require sedation or anesthesia should be performed at hospitals equipped to handle any complications that may ensue. Individuals with JS should have a pre-anesthesia screening by anesthesia personnel to optimize anesthesia outcomes.

Individuals with JS often have complex medical histories, making it imperative for them to be evaluated by an anesthesiology professional well in advance of elective sedation or anesthesia. This allows time for appropriate clinical evaluation and any required additional testing, ensuring that the anesthesiology professional and facility are as prepared as possible. Meeting with the family can also help educate the anesthesiology professional about the affected individual and about JS, since it is a rare condition and likely not well known to the provider. When anesthesia consultation is not possible prior to the procedure, it is imperative to ask for the anesthesia professional to meet the individual and the caregiver on the day of surgery. A full health history should be reviewed including medical issues, prior anesthetic exposures, and current medications (including any supplements). Allowing a caregiver to accompany an affected individual during induction of anesthesia may minimize pretreatment with sedatives. In addition, we recommend adherence to procedures for high-risk individuals and prolonged observation after sedation to evaluate for apnea.

Genetic counseling

Genetic counseling about the mechanism of inheritance, recurrence risk, genetic testing, and reproductive options is the standard of care for individuals with JS and their families. To date, only autosomal recessive and X-linked inheritance mechanisms have been demonstrated for JS. With autosomal recessive inheritance, parents of an affected child have a 25% recurrence risk with each pregnancy, and unaffected siblings have a 67% risk of being carriers. Since the carrier frequency for any given JS gene in outbred populations is $<1/500$, the risk of a carrier having an affected child with an unrelated partner in out-bred populations is $<1/2000$. For the one X-linked gene (*OFD1*), the recurrence risk is also 25% (50% of sons); 50% of unaffected daughters are carriers, and all

unaffected sons are non-carriers. Recurrence risk counseling in consanguineous and founder populations (e.g. Ashkenazi Jews, Hutterites, French Canadians and others) require individualized calculations. While little is known about fertility in individuals with JS, several women have had children; therefore, teenagers and adults with JS should be counseled about recurrence risk for people with rare recessive conditions at a level appropriate to their understanding. Oligogenic inheritance, where variants in >1 gene are required to cause a disorder, has been proposed to play a role in ciliopathies, [Hoefele and others 2007; Katsanis and others 2001] but no definitive examples have been published in JS;[Abu-Safieh and others 2012; Phelps and others 2018] therefore, we recommend against clinical counseling for oligogenic inheritance at this time. For details about molecular confirmation of the diagnosis, see the “Molecular diagnosis of JS” section above.

Reproductive options for couples with a prior child or fetus affected by JS are best explored through formal genetic counseling. Options to reduce the risk of having a second affected child may include preimplantation genetic diagnosis for a known pathogenic variant, use of donor egg or sperm, prenatal diagnosis through chorionic villus sampling (CVS) or amniocentesis, or adoption. Couples considering gamete donation should avoid donation by relatives, given their increased risk of being carriers for the same pathogenic variant. For couples in whom the cause is unknown, egg donation may be preferred over sperm donation since the mother may be a carrier for a pathogenic OFD1 variant. Prenatal imaging such as ultrasound and fetal MRI may be used to evaluate for features of JS during pregnancy. Imaging abnormalities may suggest a diagnosis of JS, but the absence of abnormalities is not a guarantee that the fetus is unaffected. The decision to pursue or decline alternative reproductive options is very personal, and discussion with a geneticist or genetic counselor may provide an opportunity to explore all available options. In the United States, genetic counseling providers can be identified through the National Society of Genetic Counselors (www.nsgc.org).

Adjusted follow-up recommendations based on gene-phenotype associations

While general healthcare recommendations apply to all individuals with JS, gene-phenotype correlations can be used to adjust management based on the specific underlying genetic etiology. *CEP290* dysfunction is strongly associated with retinal dystrophy and to a lesser extent kidney disease; therefore, individuals with *CEP290*-related JS should have more frequent monitoring for retinal and kidney disease as described above. Similarly, loss of *TMEM67* function is strongly associated with coloboma and liver fibrosis,[Bachmann-Gagescu and others 2015a; Brancati and others 2007; Brancati and others 2009; Doherty and others 2010; Vilboux and others 2017a] monitoring for liver fibrosis should be performed more frequently. Weaker associations also support a higher risk for retinal disease with *AHI1*, and kidney disease with *TMEM67* and *RPGRIP1L*. Conversely, individuals with loss of *TMEM67* function appear less likely to develop retinal disease; consequently, less frequent monitoring of retinal involvement may be acceptable in these individuals.[Bachmann-Gagescu and others 2015a]

Precision treatments

Precision treatments are treatments specifically targeting the genetic cause or biological mechanism of a disorder. Currently, precision treatments for JS are only available as part of research studies, if at all. Although not yet used for targeting a JS gene, direct gene therapy has been used to improve visual function for specific types of retinal dystrophy by direct retinal injection of expression vectors in humans.[Russell and others 2017] Future trials are likely to involve the *CEP290* gene, a major cause of Leber congenital amaurosis and JS.[Maeder and others 2019; Mookherjee and others 2018] Alternatively, antisense oligonucleotides can augment gene function by blocking aberrant splicing[Cideciyan and others 2019; Dulla and others 2018] or by causing exons with deleterious

variants to be skipped.[Ramsbottom and others 2018] These treatments are still in early development for JS, but have been used for other disorders in humans such as spinal muscular atrophy.[Finkel and others 2017] Future medications targeting specific pathways that are disrupted in JS may be beneficial, but this work is also in its infancy.[Hynes and others 2014; Kim and others 2018] Some promising medications developed for ciliopathy-related conditions in animal models have been ineffective or harmful in humans;[Ruggenenti and others 2016; Serra and others 2010; Walz and others 2010] therefore, cautious optimism is in order about the timeline for future effective treatments.

Family support

While caring for a loved one with significant healthcare needs and/or neurodevelopmental disability is often very rewarding, it can also be emotionally and cognitively challenging. Families in need can draw support from other family members, medical providers, mental health providers, social workers, community resources, and family support organizations like the Joubert Syndrome and Related Disorders Foundation (<https://jsrdf.org>), the Asociación de Familias con Síndrome de Joubert y Trastornos Relacionados (<https://asociacionfabert.wixsite.com/fabert>), Associazione Italiana Sindrome di Joubert e Atassie Congenite (<http://www.aisjac.net>), and the Ciliopathy Alliance (www.ciliopathyalliance.org). In addition, “respite care” can provide primary caregiver(s) breaks from caring for others so that they can rest and care for themselves. Information about respite care resources is available from a variety of providers, and at <https://www.childwelfare.gov/topics/preventing/prevention-programs/respite/> and <https://archrespite.org/respitelocator> for the United States.

Conclusions

Given the multisystem nature of JS in the majority of individuals, ideal clinical management requires careful regular follow-up for early detection and optimal management of complications. To assist families in receiving the best medical care possible, one provider should take the lead, performing the baseline and follow-up evaluations (Tables 2-4), and referring the individual for specialized care when specific organs are involved. In this manner, all the relevant information for a given individual can be centralized for coordination of care. In addition to diagnostic, carrier, and prenatal testing, a molecular diagnosis allows prognostic sub-stratification that can guide monitoring and treatment of progressive features. Moreover, gene-specific treatments may become available in the future and will require the knowledge of the gene defect in each individual.

Ongoing research is required to identify all of the genetic causes of JS so that every individual can receive a genetic diagnosis and ultimately precision healthcare tailored to that diagnosis. Further study of phenotypic outcomes will allow more precise prognostic information, including more accurate estimates of the age of onset and long-term evolution for each of the progressive features. In addition, less-characterized phenotypic features require systematic assessment, in particular, the behavioral and psychiatric issues that often present major problems for the affected individual and their family. Finally, existing supportive treatments need to be optimized and precision treatments need to be developed and implemented.

Acknowledgement/Dedication

During the long process of drafting these healthcare recommendations, Andrea Poretti, MD died suddenly. Andrea was a brilliant child neurologist with extensive neuroimaging expertise who was very devoted to his patients, research colleagues, and family. He is deeply missed by all.




Figure 1. Diagnostic features of Joubert syndrome on MRI. **(A)** Molar Tooth Sign (MTS) on T2-weighted axial images due to the combination of long, thick superior cerebellar peduncles (the roots of the tooth) and a deep interpeduncular fossa (the cutting surface of the tooth). This appearance is not always captured in a single plane, so it is important to evaluate the MRI as a whole rather than relying on a single image. **(B)** Superior cerebellar foliar dysplasia (bracket) on axial T2-weighted images, sometimes seen in the absence of the MTS in individuals carrying pathogenic variants in the JS-associated genes (note that the folia at this level are usually shaped like a U or V). **(C)** Horizontally-oriented superior cerebellar peduncle (white arrowhead) on T1-weighted parasagittal image; **(D)** Vermis hypoplasia (outline), elevated roof of the 4th ventricle, and rostrally displaced fastigium on T1-weighted sagittal image; **(E)** Long, thick superior cerebellar peduncles (black arrowhead) T2-weighted coronal image; **(F)** Appearance of a cerebellar cleft (black arrow indicating fluid at the cerebellar midline) on T2-weighted coronal image. **(A'-F')** similar images from an unaffected individual of the same age.

Table 1. Genes associated with Joubert syndrome and risk of complications

Gene	Chr	% ¹	Retina ²	Kidney ²	Liver ²	Other	References
<i>AHI1</i>	6	5-10	↑	-	-		[Dixon-Salazar and others 2004; Ferland and others 2004]
<i>ARL13B</i>	3	<2	-	-	-		[Cantagrel and others 2008]
<i>ARL3</i>	10	Unk	-	-	-		[Alkanderi and others 2018]
<i>ARMC9</i>	2	<2	-	-	-		[Van De Weghe and others 2017]
<i>B9D1</i>	17	<2	-	-	-		[Romani and others 2014]
<i>B9D2</i>	19	<2	-	-	-		[Bachmann-Gagescu and others 2015a]
<i>C2CD3</i>	11	<2	-	-	-	Skeletal dysplasia	[Thauvin-Robinet and others 2014]
<i>CC2D2A</i>	4	5-10	-	-	-		[Gorden and others 2008]
<i>CEP104</i>	1	<2	-	-	-		[Srouf and others 2015]
<i>CEP120</i>	5	Unk	-	-	-	Skeletal dysplasia	[Roosing and others 2016; Shaheen and others 2015]
<i>CEP290</i>	12	5-10	↑↑	↑	-	Encephalocele	[Sayer and others 2006; Valente and others 2006]
<i>CEP41</i>	7	<2	-	-	-		[Lee and others 2012a]
<i>CPLANE1</i>	5	5-10	-	-	-	PD, OFD	[Srouf and others 2012b]
<i>CSPP1</i>	8	2-5	-	↓	-		[Akizu and others 2014; Shaheen and others 2014; Tuz and others 2014]
<i>FAM149B1</i>		Unk	-	-	-	PD, OFD	[Shaheen and others 2019]
<i>HYLS1</i>	11	<2	-	-	-		[Oka and others 2016]
<i>IFT172</i>	2	<2	-	-	-	Skeletal dysplasia	[Halbritter and others 2013]
<i>INPP5E</i>	9	2-5	-	-	-		[Bielas and others 2009]
<i>KIAA0556</i>	16	<2	-	-	-		[Sanders and others 2015]
<i>KIAA0586</i>	14	2-5	-	-	-		[Bachmann-Gagescu and others 2015b; Malicdan and others 2015; Stephen and others 2015]
<i>KIAA0753</i>	17	<2	-	-	-		[Chevrier and others 2016]
<i>KIF7</i>	15	<2	-	-	-	ACC, PD, Skeletal dysplasia	[Dafinger and others 2011; Putoux and others 2011]
<i>MKS1</i>	17	2-5	-	-	-		[Romani and others 2014]
<i>NPHP1</i>	2	<2	↑	↑↑	-		[Parisi and others 2004]
<i>OFD1</i>	X	<2	-	-	-	Encephalocele, OFD, PCD	[Coene and others 2009]
<i>PDE6D</i>	2	<2	-	-	-		[Thomas and others 2014]
<i>PIBF1</i>	13	<2	-	↑	-		[Wheway and others 2015]
<i>RPGRIP1L</i>	16	2-5	-	↑	-		[Arts and others 2007; Delous and others 2007]
<i>SUFU</i>	10	Unk	-	-	-		[De Mori and others 2017]
<i>TCTN1</i>	12	<2	-	-	-		[Garcia-Gonzalo and others 2011]
<i>TCTN2</i>	12	<2	-	↑	-	Encephalocele, coloboma	[Sang and others 2011]
<i>TCTN3</i>	10	<2	-	-	-		[Thomas and others 2012]
<i>TMEM107</i>	17	<2	-	-	-	OFD	[Lambacher and others 2016]
<i>TMEM138</i>	11	<2	-	-	-		[Lee and others 2012b]
<i>TMEM216</i>	11	2-5	-	-	-		[Edvardson and others 2010; Valente and others 2010]
<i>TMEM231</i>	16	<2	-	-	-		[Srouf and others 2012a]
<i>TMEM237</i>	2	<2	-	-	-		[Huang and others 2011]
<i>TMEM67</i>	8	5-10	↓	↑	↑↑	Coloboma, PD	[Baala and others 2007]

¹Based on panel sequencing 572 families in the University of Washington cohort

Abbreviations: ACC = Agenesis of the Corpus Callosum, Chr = Chromosome, OFD = Oral Facial Digital features, PCD = Primary Ciliary Dyskinesia, PD = PolyDactyly, Unk = Unknown (not found in the UW cohort)

²↑ weak positive association, ↑↑ strong positive association, ↓ weak negative association, - no known association (all studies to date are underpowered to identify small differences in risk associated with less frequent genetic causes)

Note: The following genes are not listed due to lack of sufficient evidence that they are associated with JS (only one family, insufficient clinical information, and/or lack of biallelic variants): *TTC21B* (no biallelic variants in JS, variants reported in families with other ciliopathies),[Davis and others 2011] *ZNF423* (one family with possible JS),[Chaki and others 2012] *CLUAP1* (one family with JS),[Johnston and others 2017] *EXOC8* (one family with JS),[Dixon-Salazar and others 2012] *CELSR2* (one family in each of two papers, variants not reported for one family),[Shaheen and others 2016; Vilboux and others 2017b] *POC1B* (one family),[Beck and others 2014] *CEP164* (one family with JS, variants reported in families with other ciliopathies),[Chaki and others 2012; Vilboux and others 2017a] *INTU* (insufficient imaging informaton in several patients with ciliopathy phenotypes).[Bruehl and others 2017; Bruehl and others 2018; Toriyama and others 2016]

Table 2. Prevalence, onset and management of medical complications associated with Joubert syndrome

	Prevalence (%) ¹	Onset	Specialized tests/referrals to consider based on Hx/PE/routine tests	Management/ Treatment
Neurologic				
MTS	100	congenital		
Encephalocele	8	congenital	MRI, Neurosurgery consultation	Surgery if clinically indicated
Hydrocephalus	rare	unknown	MRI (or US or CT) if clinically indicated, Neurosurgery consultation	Shunt if clinically indicated
Dystonic episodes	rare	unknown	Neurology consultation	Behavioral (remove inciting factors), medications trials, tooth removal for severe biting
Seizures	>10	unknown	EEG, Neurology consultation	Anti-epileptic treatment as required
Feeding problems Dysphagia	common	congenital	Video fluoroscopic swallow study chest X-ray if s/s	Feeding therapy, thickened feeds, tube feeding
Cognitive and developmental delays	common	congenital	Standardized neurocognitive testing (private or school-based), annual school program planning ²	Special education support Speech therapy, consider alternative communication strategies and/or augmentative communication devices Occupational Therapy Physiotherapy
Ocular motor apraxia, ophthalmoplegia	~80	congenital	Ophthalmology consultation	Supportive interventions for visual impairment
Behavior/Psychiatric				
Self-injury, Anxiety, Stereotypies, Depression, ADHD, Hallucinations, Sleep disturbances	unknown	early childhood to adulthood	Functional behavioral analysis, developmental pediatrics or psychiatry consultation, sleep medicine evaluation	Behavioral interventions, medications
Respiratory				
Abnormal respiratory control	~70	congenital	Sleep medicine/pulmonology polysomnography	Respiratory support if indicated, home monitoring controversial, no evidence for or against caffeine
Obstructive apnea	unknown	neonatal to adulthood	Sleep medicine/ pulmonology/ ENT consultation polysomnography, echocardiogram	Supplementary oxygen, PAP, T/A, if indicated
Restrictive lung disease (w/ skeletal dysplasia)	rare	congenital	Chest X-ray Pulmonology consultation	Respiratory support if indicated, thoracic expansion if indicated
Ophthalmology+				
Strabismus	>31	neonatal to adolescence	Cover-uncover test, Ophthalmology consultation	Spectacles, patching or pupillary dilation, surgery with caution due to underlying neurological abnormality
Ptosis	>19	congenital	Ophthalmology consultation	Surgery if indicated

Retinal dystrophy	30	neonatal to adulthood	Ophthalmology consultation, consider OCT, ERG, FAF if indicated	Supportive interventions for visual impairment
Coloboma	17	congenital	Ophthalmology consultation	Supportive interventions for visual impairment
Kidney				
Fibrocystic kidney disease/Nephronophthisis /cystic dysplasia	25	neonatal to adulthood	Nephrology consultation bone density scan, kidney biopsy	Medications for support of decreasing kidney function; diagnosis and treatment of hypertension, prevention of dehydration in early disease and fluid overload in late disease; in case of ESKD: dialysis, kidney transplantation
Liver				
Congenital Hepatic Fibrosis	14	congenital to adulthood	GI/Hepatology consultation	Medications for management of portal hypertension ablation of varices, porto-systemic shunting if indicated, liver transplant
Musculoskeletal				
Polydactyly	15	congenital	X-ray, Orthopedics consultation	Surgery if indicated for functional or aesthetic reasons
Scoliosis	>5	childhood-adulthood	X-ray, Orthopedics consultation	Surgery if indicated for respiratory compromise or positioning (rare)
Skeletal Dysplasia	rare	congenital	X-ray, Skeletal dysplasia specialist consultation	Surgery if indicated for respiratory issues (rare)
Other				
Endocrine	4-6	infancy to adulthood	Laboratory testing based on clinical suspicion	Hormone replacement as required
Congenital heart disease	rare	congenital	Echocardiogram, chest X-ray, cardiology consultation	Based on specific lesion
Hearing loss	~3	neonatal to childhood	Audiology evaluation	Ear tubes for chronic otitis media, hearing aids, cochlear implants (rare)
Cleft palate	>3	congenital	Craniofacial consultation	Surgery if indicated
Oral features, frenula, hamartoma	>4	congenital	NA	Surgery if indicated (for function or comfort – rare)
Feeding difficulty, drooling	common	congenital	Clinical feeding evaluation, video fluoroscopic swallow study	Feeding therapy, tube feeding, medications for drooling
Genetics				
Molecular diagnosis	NA	NA	Genetics consultation, genetic testing	Prognostic, recurrence risk, and reproductive counseling, Stratification into different risk groups for specific complications, Assignment to future gene-specific treatments

¹based on Bachmann-Gagescu, et al. 2015, the prevalence of each feature likely depends on the specific population evaluated

²Individualized Educational Plan (IEP) in the United States

Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, ENT = Ear Nose Throat (Otorhinolaryngology), ESKD = End Stage Kidney Disease, FAF = Fundus Auto-Fluorescence, Hx = History, mvt = movement, PAP = Positive Airway Pressure (continuous, bilevel or other), PE = Physical Exam, s/s signs and symptoms, T/A = Tonsillectomy/Adenoidectomy, US = UltraSound

Table 3. History and physical exam checklist for managing medical provider.

	At diagnosis	Routine (~yearly)	History	Physical examination	
Neurologic - head					
Consequences of the MTS	X	X	Hypotonia, developmental delay, ataxia	Neurological exam	
Encephalocele	X		“Bump on head?” (usually occipital)	Palpate skull	
Hydrocephalus	X	X	Increasing head size (<2 yrs), headaches, vomiting	OFC plot, fontanelles	
Dystonic episodes	X	X	s/s	Muscle tone	
Seizures	X	X	s/s		
Cognition/psychiatric/Behavior	X	X	Self-injury, Anxiety, Stereotypies, Depression, ADHD, Hallucinations	Std developmental and psychiatric assessments, focus on stereotypies, injury	
Eyes					
Consequences of the MTS: ocular motor apraxia, nystagmus, ophthalmoplegia	X	X	Head shaking Tracking with head mvt	Focus on eye mvts	
Strabismus	X	X	Eye deviation, head tilt	Pupillary alignment, cover-uncover test	
Ptosis	X	X	Drooping eyelid, chin up position (backward head tilt)	Drooping eyelid, chin up position (backward head tilt)	
Retinal dystrophy	X	X	Visual impairment particularly in low light, photophobia	Visual acuity	
Coloboma	X		Visual impairment (only with macula or optic nerve involvement)		
Respiratory					
Consequences of the MTS: Abnormal respiratory control	X	X	Apnea, tachypnea, sleep disordered breathing	Std pulmonary	Respiratory rhythm (awake and asleep)
Obstructive apnea	X	X	Apnea, tachypnea, snoring, sleep disordered breathing		Focus on airway
Restrictive lung disease (w/ skeletal dysplasia)	X		Small chest, tachypnea, respiratory distress	Std pulmonary	
Kidney					
Fibrocystic kidney disease/ Nephronophthisis/cystic dysplasia	X	X	Growth failure, anemia, polyuria, polydipsia, 2ndary enuresis, urinary concentration defect, osteopenia, fatigue, decreased appetite, hypertension, dehydration/ fluid overload	Growth parameters, blood pressure, pallor	
Liver					
Congenital Hepatic Fibrosis	X	X	s/s portal hypertension, splenomegaly, varices, GI bleeding	Splenomegaly, spider angiomas (chest, arms, neck)	
Musculoskeletal					
Polydactyly	X		Functional difficulty	Std musculoskeletal	
Scoliosis	X	X	Change in posture		
Skeletal Dysplasia	X		Short stature, small chest, short limbs, respiratory status		

Other				
Endocrine	X	X	s/s growth failure, hypothyroidism, diabetes mellitus, micropenis, abnormal puberty	Heart rate, blood pressure, growth parameters, genital exam
Congenital heart disease	X		Murmur, feeding or exercise intolerance	Heart rate, blood pressure (arm and leg), oxygen saturation, cardiac exam, consider echocardiogram
Hearing loss	X	X	Delayed speech, decreased response to sounds	Newborn and annual hearing screening
Cleft palate	X		Nasal speech, nasal regurgitation, feeding difficulties	Std oral
Oral features, frenula, hamartoma	X		s/s	

Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder, MTS = Molar Tooth Sign, mvt = movement, OFC = Occipital-Frontal Circumference, s/s = signs and symptoms, std = standard

Table 4. Lab and imaging test checklist (ordered by managing medical provider, with referral to specialists as required based on findings).

	At diagnosis	Approximate interval (years)	As required based on Hx/PE/routine findings	Abnormal test results reflect involvement				
				renal	liver	resp	retinal	other
Blood/urine tests								
Molecular genetic diagnosis	X							
CBC	X	1-2	X	anemia	Hypersplenism (↓ing plts)			
Serum electrolytes	X	1-2	X	CKD		Abnormal respiratory control, obstructive apnea, restrictive lung disease		
Capillary blood gas			X			Abnormal respiratory control, obstructive apnea restrictive lung disease		
creatinine (+cystatin C when available)	X	1-2	X	CKD				
Ca, Ph, PTH	X		X	CKD				
Urine osmolality	X	1-2	X	CKD				
Imaging tests								
Abdominal US¹								
Kidney	X	*	X	Increased echogenicity, loss of corticomedullary differentiation, microcysts, macrocysts, urological malformations				
Liver	X		X		Increased echogenicity			
Spleen (size)¹	X	2-3	X		Increasing spleen size			

MRI	X		X					Dx confirmation, new neurological symptoms
Head CT / US			X					Hydrocephalus
Chest X-ray			X			Obstructive apnea/ aspiration/pulmonary hypertension		Skeletal dysplasia
Specialized tests (requiring referral to specialist)								
Comprehensive eye exam	X	1-2	X				Retinal dystrophy, coloboma, strabismus, refractive error, amblyopia	
OCT / ERG			X				Retinal dystrophy	
Bone densitometry			X	CKD				
Upper GI endoscopy			X		Esophageal or gastric varices			
EEG			X					Seizures
Video fluoroscopic swallow study			X					Dysphagia
Standardized psychological assessment for school planning	X	3	X					

1 note that typically, evaluation of spleen size needs to be specifically requested as part of an abdominal ultrasound that will also include evaluation of the liver and kidneys
* during adolescence

Abbreviations: ↑ing = increasing over time, ↓ing = decreasing over time, BUN = Blood Urea Nitrogen, Ca = Calcium, CBC = complete blood count, CKD = Chronic Kidney Disease, CT = Computed Tomography, ERG = ElectroRetinoGram, GGT = gamma glutamyltranspeptidase, GI = Gastrointestinal, MRI = Magnetic Resonance Imaging, OCT = Optical Coherence Tomography, Ph = Phosphorus, plts = platelets, PTH = ParaThyroid Hormone, s/s = signs and symptoms, std = standard, US = UltraSound

References

- Abu-Safieh L, Al-Anazi S, Al-Abdi L, Hashem M, Alkuraya H, Alamr M, Sirelkhatim MO, Al-Hassnan Z, Alkuraya B, Mohamed JY, Al-Salem A, Alrashed M, Faqeih E, Softah A, Al-Hashem A, Wali S, Rahbeeni Z, Alsayed M, Khan AO, Al-Gazali L, Taschner PE, Al-Hazzaa S, Alkuraya FS. 2012. In search of triallelism in Bardet-Biedl syndrome. *European journal of human genetics* : EJHG 20(4):420-427.
- Akizu N, Silhavy JL, Rosti RO, Scott E, Fenstermaker AG, Schroth J, Zaki MS, Sanchez H, Gupta N, Kabra M, Kara M, Ben-Omran T, Rosti B, Guemez-Gamboa A, Spencer E, Pan R, Cai N, Abdellateef M, Gabriel S, Halbritter J, Hildebrandt F, van Bokhoven H, Gunel M, Gleeson JG. 2014. Mutations in CSPP1 lead to classical Joubert syndrome. *American journal of human genetics* 94(1):80-86.
- Aldinger KA, Mosca SJ, Tetreault M, Dempsey JC, Ishak GE, Hartley T, Phelps IG, Lamont RE, O'Day DR, Basel D, Gripp KW, Baker L, Stephan MJ, Bernier FP, Boycott KM, Majewski J, Parboosingh JS, Innes AM, Doherty D. 2014. Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophy. *American journal of human genetics* 95(2):227-234.
- Alkanderi S, Molinari E, Shaheen R, Elmaghloob Y, Stephen LA, Sammut V, Ramsbottom SA, Srivastava S, Cairns G, Edwards N, Rice SJ, Ewida N, Alhashem A, White K, Miles CG, Steel DH, Alkuraya FS, Ismail S, Sayer JA. 2018. ARL3 Mutations Cause Joubert Syndrome by Disrupting Ciliary Protein Composition. *American journal of human genetics* 103(4):612-620.
- Andermann F, Andermann E, Ptito A, Fontaine S, Joubert M. 1999. History of Joubert syndrome and a 30-year follow-up of the original proband. *Journal of child neurology* 14(9):565-569.
- Arts HH, Doherty D, van Beersum SE, Parisi MA, Letteboer SJ, Gorden NT, Peters TA, Marker T, Voeselek K, Kartono A, Ozyurek H, Farin FM, Kroes HY, Wolfrum U, Brunner HG, Cremers FP, Glass IA, Knoers NV, Roepman R. 2007. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. *Nature genetics* 39(7):882-888.
- Aslan H, Ulker V, Gulcan EM, Numanoglu C, Gul A, Agar M, Ark HC. 2002. Prenatal diagnosis of Joubert syndrome: a case report. *Prenatal diagnosis* 22(1):13-16.
- Atalay YO, Soylu AI, Tekcan D. 2016. Anaesthesia and orphan disease: sedation with ketofol in two patients with Joubert syndrome. *European journal of anaesthesiology* 33(11):868-869.
- Baala L, Romano S, Khaddour R, Saunier S, Smith UM, Audollent S, Ozilou C, Faivre L, Laurent N, Foliguet B, Munnich A, Lyonnet S, Salomon R, Encha-Razavi F, Gubler MC, Boddaert N, de Lonlay P, Johnson CA, Vekemans M, Antignac C, Attie-Bitach T. 2007. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. *American journal of human genetics* 80(1):186-194.
- Bachmann-Gagescu R, Dempsey JC, Phelps IG, O'Roak BJ, Knutzen DM, Rue TC, Ishak GE, Isabella CR, Gorden N, Adkins J, Boyle EA, de Lacy N, O'Day D, Alswaid A, Ramadevi AR, Lingappa L, Lourenco C, Martorell L, Garcia-Cazorla A, Ozyurek H, Haliloglu G, Tuysuz B, Topcu M, Chance P, Parisi MA, Glass IA, Shendure J, Doherty D. 2015a. Joubert syndrome: a model for untangling recessive disorders with extreme genetic heterogeneity. *Journal of medical genetics* 52(8):514-522.
- Bachmann-Gagescu R, Phelps IG, Dempsey JC, Sharma VA, Ishak GE, Boyle EA, Wilson M, Marques Lourenco C, Arslan M, Shendure J, Doherty D. 2015b. KIAA0586 is Mutated in Joubert Syndrome. *Human mutation* 36(9):831-835.
- Beck BB, Phillips JB, Bartram MP, Wegner J, Thoenes M, Pannes A, Sampson J, Heller R, Gobel H, Koerber F, Neugebauer A, Hedergott A, Nurnberg G, Nurnberg P, Thiele H, Altmuller J, Tolia MR, Staubach S, Boycott KM, Valente EM, Janecke AR, Eisenberger T, Bergmann C, Tebbe L, Wang Y, Wu Y, Fry AM, Westerfield M, Wolfrum U, Bolz HJ. 2014. Mutation of POC1B in a severe syndromic retinal ciliopathy. *Human mutation* 35(10):1153-1162.
- Bhaskar P, John J, Sivamurthy SK, Lone RA, Tysarowski PA, Riyas MK, Syed SA, Bhat AN, Sallehuddin A. 2013. Anesthetic management of an infant with Joubert syndrome for cardiac surgery. *Journal of clinical anesthesia* 25(6):488-490.

- Bielas SL, Silhavy JL, Brancati F, Kisseleva MV, Al-Gazali L, Sztriha L, Bayoumi RA, Zaki MS, Abdel-Aleem A, Rosti RO, Kayserili H, Swistun D, Scott LC, Bertini E, Boltshauser E, Fazzi E, Travaglini L, Field SJ, Gayral S, Jacoby M, Schurmans S, Dallapiccola B, Majerus PW, Valente EM, Gleeson JG. 2009. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. *Nature genetics* 41(9):1032-1036.
- Boltshauser E, Herdan M, Dumermuth G, Isler W. 1981. Joubert syndrome: clinical and polygraphic observations in a further case. *Neuropediatrics* 12(2):181-191.
- Braddock BA, Farmer JE, Deidrick KM, Iverson JM, Maria BL. 2006. Oromotor and communication findings in joubert syndrome: further evidence of multisystem apraxia. *Journal of child neurology* 21(2):160-163.
- Braddock SR, Henley KM, Maria BL. 2007. The face of Joubert syndrome: a study of dysmorphology and anthropometry. *American journal of medical genetics Part A* 143A(24):3235-3242.
- Brancati F, Barrano G, Silhavy JL, Marsh SE, Travaglini L, Bielas SL, Amorini M, Zablocka D, Kayserili H, Al-Gazali L, Bertini E, Boltshauser E, D'Hooghe M, Fazzi E, Fenerci EY, Hennekam RC, Kiss A, Lees MM, Marco E, Phadke SR, Rigoli L, Romano S, Salpietro CD, Sherr EH, Signorini S, Stromme P, Stuart B, Sztriha L, Viskochil DH, Yuksel A, Dallapiccola B, Valente EM, Gleeson JG. 2007. CEP290 mutations are frequently identified in the oculo-renal form of Joubert syndrome-related disorders. *American journal of human genetics* 81(1):104-113.
- Brancati F, Dallapiccola B, Valente EM. 2010. Joubert Syndrome and related disorders. *Orphanet J Rare Dis* 5:20.
- Brancati F, Iannicelli M, Travaglini L, Mazzotta A, Bertini E, Boltshauser E, D'Arrigo S, Emma F, Fazzi E, Gallizzi R, Gentile M, Loncarevic D, Mejaski-Bosnjak V, Pantaleoni C, Rigoli L, Salpietro CD, Signorini S, Stringini GR, Verloes A, Zablocka D, Dallapiccola B, Gleeson JG, Valente EM. 2009. MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. *Human mutation* 30(2):E432-442.
- Brooks BP, Zein WM, Thompson AH, Mokhtarzadeh M, Doherty DA, Parisi M, Glass IA, Malicdan MC, Vilboux T, Vemulapalli M, Mullikin JC, Gahl WA, Gunay-Aygun M. 2018. Joubert Syndrome: Ophthalmological Findings in Correlation with Genotype and Hepatorenal Disease in 99 Patients Prospectively Evaluated at a Single Center. *Ophthalmology* 125(12):1937-1952.
- Bruel AL, Franco B, Duffourd Y, Thevenon J, Jegu L, Lopez E, Deleuze JF, Doummar D, Giles RH, Johnson CA, Huynen MA, Chevrier V, Burglen L, Morleo M, Desgueres I, Pierquin G, Doray B, Gilbert-Dussardier B, Reversade B, Steichen-Gersdorf E, Baumann C, Panigrahi I, Fargeot-Espaliat A, Dieux A, David A, Goldenberg A, Bongers E, Gaillard D, Argente J, Aral B, Gigot N, St-Onge J, Birnbaum D, Phadke SR, Cormier-Daire V, Eguether T, Pazour GJ, Herranz-Perez V, Goldstein JS, Pasquier L, Loget P, Saunier S, Megarbane A, Rosnet O, Leroux MR, Wallingford JB, Blacque OE, Nachury MV, Attie-Bitach T, Riviere JB, Faivre L, Thauvin-Robinet C. 2017. Fifteen years of research on oral-facial-digital syndromes: from 1 to 16 causal genes. *Journal of medical genetics* 54(6):371-380.
- Bruel AL, Levy J, Elenga N, Defo A, Favre A, Lucron H, Capri Y, Perrin L, Passemard S, Vial Y, Tabet AC, Faivre L, Thauvin-Robinet C, Verloes A. 2018. INTU-related oral-facial-digital syndrome type VI: A confirmatory report. *Clinical genetics* 93(6):1205-1209.
- Budny B, Chen W, Omran H, Fliegauf M, Tzschach A, Wisniewska M, Jensen LR, Raynaud M, Shoichet SA, Badura M, Lenzner S, Latos-Bielenska A, Ropers HH. 2006. A novel X-linked recessive mental retardation syndrome comprising macrocephaly and ciliary dysfunction is allelic to oral-facial-digital type I syndrome. *Human genetics* 120(2):171-178.
- Bulgheroni S, D'Arrigo S, Signorini S, Briguglio M, Di Sabato ML, Casarano M, Mancini F, Romani M, Alfieri P, Battini R, Zoppello M, Tortorella G, Bertini E, Leuzzi V, Valente EM, Riva D. 2016. Cognitive, adaptive, and behavioral features in Joubert syndrome. *American journal of medical genetics Part A* 170(12):3115-3124.
- Buntenbroich S, Dullenkopf A. 2013a. Anesthesia recommendations for patients suffering from Joubert syndrome. In: Münster T, editor. *orphananesthesia*.
- Buntenbroich S, Dullenkopf A. 2013b. Total intravenous anesthesia in a patient with Joubert-Boltshauser syndrome. *Paediatric anaesthesia* 23(2):204-205.

- Cantagrel V, Silhavy JL, Bielas SL, Swistun D, Marsh SE, Bertrand JY, Audollent S, Attie-Bitach T, Holden KR, Dobyns WB, Traver D, Al-Gazali L, Ali BR, Lindner TH, Caspary T, Otto EA, Hildebrandt F, Glass IA, Logan CV, Johnson CA, Bennett C, Brancati F, Valente EM, Woods CG, Gleeson JG. 2008. Mutations in the cilia gene ARL13B lead to the classical form of Joubert syndrome. *American journal of human genetics* 83(2):170-179.
- Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I, Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B, Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O'Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY, Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomei J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A, Otto EA, Hildebrandt F. 2012. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. *Cell* 150(3):533-548.
- Chevrier V, Bruel AL, Van Dam TJ, Franco B, Lo Scalzo M, Lembo F, Audebert S, Baudalet E, Isnardon D, Bole A, Borg JP, Kuentz P, Thevenon J, Burglen L, Faivre L, Riviere JB, Huynen MA, Birnbaum D, Rosnet O, Thauvin-Robinet C. 2016. OFIP/KIAA0753 forms a complex with OFD1 and FOR20 at pericentriolar satellites and centrosomes and is mutated in one individual with oral-facial-digital syndrome. *Human molecular genetics* 25(3):497-513.
- Cideciyan AV, Jacobson SG, Drack AV, Ho AC, Charng J, Garafalo AV, Roman AJ, Sumaroka A, Han IC, Hochstedler MD, Pfeifer WL, Sohn EH, Tael M, Schwartz MR, Biasutto P, Wit W, Cheetham ME, Adamson P, Rodman DM, Platenburg G, Tome MD, Balikova I, Nerinckx F, Zaeytijd J, Van Cauwenbergh C, Leroy BP, Russell SR. 2019. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. *Nature medicine* 25(2):225-228.
- Coene KL, Roepman R, Doherty D, Afroze B, Kroes HY, Letteboer SJ, Ngu LH, Budny B, van Wijk E, Gorden NT, Azhimi M, Thauvin-Robinet C, Veltman JA, Boink M, Kleefstra T, Cremers FP, van Bokhoven H, de Brouwer AP. 2009. OFD1 is mutated in X-linked Joubert syndrome and interacts with LCA5-encoded lebercilin. *American journal of human genetics* 85(4):465-481.
- Dafinger C, Liebau MC, Elsayed SM, Hellenbroich Y, Boltshauser E, Korenke GC, Fabretti F, Janecke AR, Ebermann I, Nurnberg G, Nurnberg P, Zentgraf H, Koerber F, Addicks K, Elsobky E, Benzing T, Schermer B, Bolz HJ. 2011. Mutations in KIF7 link Joubert syndrome with Sonic Hedgehog signaling and microtubule dynamics. *The Journal of clinical investigation* 121(7):2662-2667.
- Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG, Gyapay G, Rieger S, Tonshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attie-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N. 2011. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. *Nature genetics* 43(3):189-196.
- De Mori R, Romani M, D'Arrigo S, Zaki MS, Loreface E, Tardivo S, Biagini T, Stanley V, Musaev D, Fluss J, Micalizzi A, Nuovo S, Illi B, Chiapparini L, Di Marcotullio L, Issa MY, Anello D, Casella A, Ginevrino M, Leggins AS, Roosing S, Alfonsi R, Rosati J, Schot R, Mancini GMS, Bertini E, Dobyns WB, Mazza T, Gleeson JG, Valente EM. 2017. Hypomorphic Recessive Variants in SUFU Impair the Sonic Hedgehog Pathway and Cause Joubert Syndrome with Cranio-facial and Skeletal Defects. *American journal of human genetics* 101(4):552-563.
- Delous M, Baala L, Salomon R, Laclef C, Vierkotten J, Tory K, Golzio C, Lacoste T, Besse L, Ozilou C, Moutkine I, Hellman NE, Anselme I, Silbermann F, Vesque C, Gerhardt C, Rattenberry E, Wolf MT, Gubler MC, Martinovic J, Encha-Razavi F, Boddaert N, Gonzales M, Macher MA, Nivet H, Champion G, Bertheleme JP, Niaudet P, McDonald F, Hildebrandt F, Johnson CA, Vekemans M, Antignac C, Ruther U, Schneider-

- Maunoury S, Attie-Bitach T, Saunier S. 2007. The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. *Nature genetics* 39(7):875-881.
- Dempsey JC, Phelps IG, Bachmann-Gagescu R, Glass IA, Tully HM, Doherty D. 2017. Mortality in Joubert syndrome. *American journal of medical genetics Part A* 173(5):1237-1242.
- Dixon-Salazar T, Silhavy JL, Marsh SE, Louie CM, Scott LC, Gururaj A, Al-Gazali L, Al-Tawari AA, Kayserili H, Sztriha L, Gleeson JG. 2004. Mutations in the AHI1 Gene, Encoding Joubertin, Cause Joubert Syndrome with Cortical Polymicrogyria. *Am J Hum Genet* 75(6):979-987.
- Dixon-Salazar TJ, Silhavy JL, Udpa N, Schroth J, Bielas S, Schaffer AE, Olvera J, Bafna V, Zaki MS, Abdel-Salam GH, Mansour LA, Selim L, Abdel-Hadi S, Marzouki N, Ben-Omran T, Al-Saana NA, Sonmez FM, Celep F, Azam M, Hill KJ, Collazo A, Fenstermaker AG, Novarino G, Akizu N, Garimella KV, Sougnez C, Russ C, Gabriel SB, Gleeson JG. 2012. Exome sequencing can improve diagnosis and alter patient management. *Science translational medicine* 4(138):138ra178.
- Doherty D. 2009. Joubert syndrome: insights into brain development, cilium biology, and complex disease. *Seminars in pediatric neurology* 16(3):143-154.
- Doherty D, Glass IA, Siebert JR, Strouse PJ, Parisi MA, Shaw DW, Chance PF, Barr M, Jr., Nyberg D. 2005. Prenatal diagnosis in pregnancies at risk for Joubert syndrome by ultrasound and MRI. *Prenatal diagnosis* 25(6):442-447.
- Doherty D, Parisi MA, Finn LS, Gunay-Aygun M, Al-Mateen M, Bates D, Clericuzio C, Demir H, Dorschner M, van Essen AJ, Gahl WA, Gentile M, Gorden NT, Hikida A, Knutzen D, Ozyurek H, Phelps I, Rosenthal P, Verloes A, Weigand H, Chance PF, Dobyns WB, Glass IA. 2010. Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis). *Journal of medical genetics* 47(1):8-21.
- Dulla K, Aguila M, Lane A, Jovanovic K, Parfitt DA, Schulkens I, Chan HL, Schmidt I, Beumer W, Vorthoren L, Collin RWJ, Garanto A, Duijkers L, Brugulat-Panes A, Semo M, Vugler AA, Biasutto P, Adamson P, Cheetham ME. 2018. Splice-Modulating Oligonucleotide QR-110 Restores CEP290 mRNA and Function in Human c.2991+1655A>G LCA10 Models. *Molecular therapy Nucleic acids* 12:730-740.
- Edvardson S, Shaag A, Zenvirt S, Erlich Y, Hannon GJ, Shanske AL, Gomori JM, Ekstein J, Elpeleg O. 2010. Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is associated with a TMEM216 mutation. *American journal of human genetics* 86(1):93-97.
- Enokizono M, Aida N, Niwa T, Osaka H, Naruto T, Kurosawa K, Ohba C, Suzuki T, Saito H, Goto T, Matsumoto N. 2017. Neuroimaging findings in Joubert syndrome with C5orf42 gene mutations: A milder form of molar tooth sign and vermian hypoplasia. *Journal of the neurological sciences* 376:7-12.
- Farmer JE, Deidrick KM, Gitten JC, Fennell EB, Maria BL. 2006. Parenting stress and its relationship to the behavior of children with Joubert syndrome. *Journal of child neurology* 21(2):163-167.
- Fennell EB, Gitten JC, Dede DE, Maria BL. 1999. Cognition, behavior, and development in Joubert syndrome. *J Child Neurol* 14(9):592-596.
- Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill RS, Al-Nouri D, Al-Rumayyan A, Topcu M, Gascon G, Bodell A, Shugart YY, Ruvolo M, Walsh CA. 2004. Abnormal cerebellar development and axonal decussation due to mutations in AHI1 in Joubert syndrome. *Nat Genet* 36(9):1008-1013.
- Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC. 2017. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *The New England journal of medicine* 377(18):1723-1732.
- Fleming LR, Doherty DA, Parisi MA, Glass IA, Bryant J, Fischer R, Turkbey B, Choyke P, Daryanani K, Vemulapalli M, Mullikin JC, Malicdan MC, Vilboux T, Sayer JA, Gahl WA, Gunay-Aygun M. 2017. Prospective Evaluation of Kidney Disease in Joubert Syndrome. *Clinical journal of the American Society of Nephrology : CJASN* 12(12):1962-1973.
- Fluss J, Blaser S, Chitayat D, Akoury H, Glanc P, Skidmore M, Raybaud C. 2006. Molar tooth sign in fetal brain magnetic resonance imaging leading to the prenatal diagnosis of Joubert syndrome and related disorders. *Journal of child neurology* 21(4):320-324.

- Fortnum HM, Summerfield AQ, Marshall DH, Davis AC, Bamford JM. 2001. Prevalence of permanent childhood hearing impairment in the United Kingdom and implications for universal neonatal hearing screening: questionnaire based ascertainment study. *BMJ* 323(7312):536-540.
- Galante D, Meola S, Cinnella G, Dambrosio M. 2009. Regional caudal blockade in a pediatric patient affected by the Joubert syndrome. *Acta anaesthesiologica Scandinavica* 53(5):693-694.
- Garcia-Gonzalo FR, Corbit KC, Sirerol-Piquer MS, Ramaswami G, Otto EA, Noriega TR, Seol AD, Robinson JF, Bennett CL, Josifova DJ, Garcia-Verdugo JM, Katsanis N, Hildebrandt F, Reiter JF. 2011. A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition. *Nature genetics* 43(8):776-784.
- Gitten J, Dede D, Fennell E, Quisling R, Maria BL. 1998. Neurobehavioral development in Joubert syndrome. *J Child Neurol* 13(8):391-397.
- Gorden NT, Arts HH, Parisi MA, Coene KL, Letteboer SJ, van Beersum SE, Mans DA, Hikida A, Eckert M, Knutzen D, Alswaid AF, Ozyurek H, Dibooglu S, Otto EA, Liu Y, Davis EE, Hutter CM, Bammler TK, Farin FM, Dorschner M, Topcu M, Zackai EH, Rosenthal P, Owens KN, Katsanis N, Vincent JB, Hildebrandt F, Rubel EW, Raible DW, Knoers NV, Chance PF, Roepman R, Moens CB, Glass IA, Doherty D. 2008. CC2D2A is mutated in Joubert syndrome and interacts with the ciliopathy-associated basal body protein CEP290. *American journal of human genetics* 83(5):559-571.
- Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnicka-Worms K, Choyke P, Daryanani KT, Turkbey B, Fischer R, Bernardini I, Sincan M, Zhao X, Sandler NG, Roque A, Douek DC, Graf J, Huizing M, Bryant JC, Mohan P, Gahl WA, Heller T. 2013. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. *Gastroenterology* 144(1):112-121 e112.
- Gunay-Aygun M, Gahl WA, Heller T. 1993. Congenital Hepatic Fibrosis Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. *GeneReviews*((R)). Seattle (WA).
- Gunay-Aygun M, Parisi MA, Doherty D, Tuchman M, Tsilou E, Kleiner DE, Huizing M, Turkbey B, Choyke P, Guay-Woodford L, Heller T, Szymanska K, Johnson CA, Glass I, Gahl WA. 2009. MKS3-related ciliopathy with features of autosomal recessive polycystic kidney disease, nephronophthisis, and Joubert Syndrome. *The Journal of pediatrics* 155(3):386-392 e381.
- Habre W, Sims C, D'Souza M. 1997. Anaesthetic management of children with Joubert syndrome. *Paediatric anaesthesia* 7(3):251-253.
- Halbritter J, Bizet AA, Schmidts M, Porath JD, Braun DA, Gee HY, McInerney-Leo AM, Krug P, Filhol E, Davis EE, Airik R, Czarnecki PG, Lehman AM, Trnka P, Nitschke P, Bole-Feysot C, Schueler M, Knebelmann B, Burtey S, Szabo AJ, Tory K, Leo PJ, Gardiner B, McKenzie FA, Zankl A, Brown MA, Hartley JL, Maher ER, Li C, Leroux MR, Scambler PJ, Zhan SH, Jones SJ, Kayserili H, Tuysuz B, Moorani KN, Constantinescu A, Krantz ID, Kaplan BS, Shah JV, Hurd TW, Doherty D, Katsanis N, Duncan EL, Otto EA, Beales PL, Mitchison HM, Saunier S, Hildebrandt F. 2013. Defects in the IFT-B component IFT172 cause Jeune and Mainzer-Saldino syndromes in humans. *American journal of human genetics* 93(5):915-925.
- Hoefele J, Wolf MT, O'Toole JF, Otto EA, Schultheiss U, Deschenes G, Attanasio M, Utsch B, Antignac C, Hildebrandt F. 2007. Evidence of oligogenic inheritance in nephronophthisis. *Journal of the American Society of Nephrology : JASN* 18(10):2789-2795.
- Howie LD, Pastor PN, Lukacs SL. 2014. Use of medication prescribed for emotional or behavioral difficulties among children aged 6-17 years in the United States, 2011-2012. *NCHS data brief*(148):1-8.
- Huang L, Szymanska K, Jensen VL, Janecke AR, Innes AM, Davis EE, Frosk P, Li C, Willer JR, Chodirker BN, Greenberg CR, McLeod DR, Bernier FP, Chudley AE, Muller T, Shboul M, Logan CV, Loucks CM, Beaulieu CL, Bowie RV, Bell SM, Adkins J, Zuniga FI, Ross KD, Wang J, Ban MR, Becker C, Nurnberg P, Douglas S, Craft CM, Akimenko MA, Hegele RA, Ober C, Utermann G, Bolz HJ, Bulman DE, Katsanis N, Blacque OE, Doherty D, Parboosingh JS, Leroux MR, Johnson CA, Boycott KM. 2011. TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. *American journal of human genetics* 89(6):713-730.
- Hynes AM, Giles RH, Srivastava S, Eley L, Whitehead J, Danilenko M, Raman S, Slaats GG, Colville JG, Ajzenberg H, Kroes HY, Thelwall PE, Simmons NL, Miles CG, Sayer JA. 2014. Murine Joubert syndrome reveals

- Hedgehog signaling defects as a potential therapeutic target for nephronophthisis. *Proceedings of the National Academy of Sciences of the United States of America* 111(27):9893-9898.
- Johnston JJ, Lee C, Wentzensen IM, Parisi MA, Crenshaw MM, Sapp JC, Gross JM, Wallingford JB, Biesecker LG. 2017. Compound heterozygous alterations in intraflagellar transport protein CLUAP1 in a child with a novel Joubert and oral-facial-digital overlap syndrome. *Cold Spring Harbor molecular case studies* 3(4).
- Jonas BS, Gu Q, Albertorio-Diaz JR. 2013. Psychotropic medication use among adolescents: United States, 2005-2010. *NCHS data brief*(135):1-8.
- Joubert M, Eisenring JJ, Robb JP, Andermann F. 1969. Familial agenesis of the cerebellar vermis. A syndrome of episodic hyperpnea, abnormal eye movements, ataxia, and retardation. *Neurology* 19(9):813-825.
- Kamdar BB, Nandkumar P, Krishnan V, Gamaldo CE, Collop NA. 2011. Self-reported sleep and breathing disturbances in Joubert syndrome. *Pediatric neurology* 45(6):395-399.
- Karp N, Grosse-Wortmann L, Bowdin S. 2012. Severe aortic stenosis, bicuspid aortic valve and atrial septal defect in a child with Joubert Syndrome and Related Disorders (JSRD) - a case report and review of congenital heart defects reported in the human ciliopathies. *European journal of medical genetics* 55(11):605-610.
- Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski JR. 2001. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science* 293(5538):2256-2259.
- Khan AO, Oystreck DT, Seidahmed MZ, AlDrees A, Elmalik SA, Alorainy IA, Salih MA. 2008. Ophthalmic features of Joubert syndrome. *Ophthalmology* 115(12):2286-2289.
- Kim YJ, Kim S, Jung Y, Jung E, Kwon HJ, Kim J. 2018. Eupatilin rescues ciliary transition zone defects to ameliorate ciliopathy-related phenotypes. *The Journal of clinical investigation* 128(8):3642-3648.
- Kroes HY, Fransen van de Putte DE, Ravesloot CJ, Lindhout D. 2007. The birth prevalence of Joubert syndrome: a population based study in the Netherlands. *European journal of human genetics : EJHG* 15(Suppl 1).
- Kroes HY, Van Zanten BG, De Ru SA, Boon M, Mancini GM, Van der Knaap MS, Poll-The BT, Lindhout D. 2010. Is hearing loss a feature of Joubert syndrome, a ciliopathy? *International journal of pediatric otorhinolaryngology* 74(9):1034-1038.
- Lambacher NJ, Bruel AL, van Dam TJ, Szymanska K, Slaats GG, Kuhns S, McManus GJ, Kennedy JE, Gaff K, Wu KM, van der Lee R, Burglen L, Doummar D, Riviere JB, Faivre L, Attie-Bitach T, Saunier S, Curd A, Peckham M, Giles RH, Johnson CA, Huynen MA, Thauvin-Robinet C, Blacque OE. 2016. TMEM107 recruits ciliopathy proteins to subdomains of the ciliary transition zone and causes Joubert syndrome. *Nature cell biology* 18(1):122-131.
- Lee JE, Silhavy JL, Zaki MS, Schroth J, Bielas SL, Marsh SE, Olvera J, Brancati F, Iannicelli M, Ikegami K, Schlossman AM, Merriman B, Attie-Bitach T, Logan CV, Glass IA, Cluckey A, Louie CM, Lee JH, Raynes HR, Rapin I, Castroviejo IP, Setou M, Barbot C, Boltshauser E, Nelson SF, Hildebrandt F, Johnson CA, Doherty DA, Valente EM, Gleeson JG. 2012a. CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the cilium. *Nature genetics* 44(2):193-199.
- Lee JH, Silhavy JL, Lee JE, Al-Gazali L, Thomas S, Davis EE, Bielas SL, Hill KJ, Iannicelli M, Brancati F, Gabriel SB, Russ C, Logan CV, Sharif SM, Bennett CP, Abe M, Hildebrandt F, Diplas BH, Attie-Bitach T, Katsanis N, Rajab A, Koul R, Sztriha L, Waters ER, Ferro-Novick S, Woods CG, Johnson CA, Valente EM, Zaki MS, Gleeson JG. 2012b. Evolutionarily assembled cis-regulatory module at a human ciliopathy locus. *Science* 335(6071):966-969.
- Lehman AM, Eydoux P, Doherty D, Glass IA, Chitayat D, Chung BY, Langlois S, Yong SL, Lowry RB, Hildebrandt F, Trnka P. 2010. Co-occurrence of Joubert syndrome and Jeune asphyxiating thoracic dystrophy. *American journal of medical genetics Part A* 152A(6):1411-1419.
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. 2009. A new equation to estimate glomerular filtration rate. *Annals of internal medicine* 150(9):604-612.
- Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, Bumcrot D, Chao H, Ciulla DM, DaSilva JA, Dass A, Dhanapal V, Fennell TJ, Friedland AE, Giannoukos G, Gloskowski SW, Glucksmann A, Gotta GM, Jayaram H, Haskett SJ, Hopkins B, Horng JE, Joshi S, Marco E, Mepani R, Reyon D, Ta T,

- Tabbaa DG, Samuelsson SJ, Shen S, Skor MN, Stetkiewicz P, Wang T, Yudkoff C, Myer VE, Albright CF, Jiang H. 2019. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. *Nature medicine* 25(2):229-233.
- Malicdan MC, Vilboux T, Stephen J, Maglic D, Mian L, Konzman D, Guo J, Yildirimli D, Bryant J, Fischer R, Zein WM, Snow J, Vemulapalli M, Mullikin JC, Toro C, Solomon BD, Niederhuber JE, Gahl WA, Gunay-Aygun M. 2015. Mutations in human homologue of chicken talpid3 gene (KIAA0586) cause a hybrid ciliopathy with overlapping features of Jeune and Joubert syndromes. *Journal of medical genetics* 52(12):830-839.
- Maria BL, Boltshauser E, Palmer SC, Tran TX. 1999. Clinical features and revised diagnostic criteria in Joubert syndrome. *Journal of child neurology* 14(9):583-590; discussion 590-581.
- Maria BL, Hoang KB, Tusa RJ, Mancuso AA, Hamed LM, Quisling RG, Hove MT, Fennell EB, Booth-Jones M, Ringdahl DM, Yachnis AT, Creel G, Frerking B. 1997. "Joubert syndrome" revisited: key ocular motor signs with magnetic resonance imaging correlation. *Journal of child neurology* 12(7):423-430.
- Matthews NC. 1989. Anaesthesia in an infant with Joubert's syndrome. *Anaesthesia* 44(11):920-921.
- Mercado A, Pedraza L, Mayol PM, Rodriguez Santana R, Tejeda C. 1991. Joubert syndrome. Respiratory failure requiring home mechanical ventilation. *Boletin de la Asociacion Medica de Puerto Rico* 83(10):451-455.
- Mookherjee S, Chen HY, Isgrig K, Yu W, Hiriyanna S, Levron R, Li T, Colosi P, Chien W, Swaroop A, Wu Z. 2018. A CEP290 C-Terminal Domain Complements the Mutant CEP290 of Rd16 Mice In Trans and Rescues Retinal Degeneration. *Cell reports* 25(3):611-623 e616.
- Nuovo S, Bacigalupo I, Ginevrino M, Battini R, Bertini E, Borgatti R, Casella A, Micalizzi A, Nardella M, Romaniello R, Serpieri V, Zanni G, Valente EM, Vanacore N, Group JIS. 2019. Age and sex prevalence estimate of Joubert Syndrome in Italy. *Neurology* In press.
- Nuovo S, Fuiano L, Micalizzi A, Battini R, Bertini E, Borgatti R, Caridi G, D'Arrigo S, Fazzi E, Fischetto R, Ghiggeri GM, Giordano L, Leuzzi V, Romaniello R, Signorini S, Stringini G, Zanni G, Romani M, Valente EM, Emma F. 2018. Impaired urinary concentration ability is a sensitive predictor of renal disease progression in Joubert syndrome. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*.
- Oka M, Shimojima K, Yamamoto T, Hanaoka Y, Sato S, Yasuhara T, Yoshinaga H, Kobayashi K. 2016. A novel HYL51 homozygous mutation in living siblings with Joubert syndrome. *Clinical genetics* 89(6):739-743.
- Oster ME, Aucott SW, Glidewell J, Hackell J, Kochilas L, Martin GR, Phillippi J, Pinto NM, Saarinen A, Sontag M, Kemper AR. 2016. Lessons Learned From Newborn Screening for Critical Congenital Heart Defects. *Pediatrics* 137(5).
- Ozyurek H, Kayacik OE, Gungor O, Karagoz F. 2008. Rare association of Hirschsprung's disease and Joubert syndrome. *European journal of pediatrics* 167(4):475-477.
- Parisi M, Glass I. 1993. Joubert Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LH, Stephens K, Amemiya A, editors. *GeneReviews*((R)). Seattle (WA).
- Parisi MA, Bennett CL, Eckert ML, Dobyns WB, Gleeson JG, Shaw DW, McDonald R, Eddy A, Chance PF, Glass IA. 2004. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. *Am J Hum Genet* 75(1):82-91.
- Parisi MA, Glass IA. 2006. Joubert syndrome. In: *GeneReviews at GeneTests-GeneClinics: Medical Genetics Information Resource* [database online]. Copyright, University of Washington, Seattle 1997-2006 Available at at <http://www.geneclinics.org> or <http://www.genetests.org>. Seattle.
- Phelps IG, Dempsey JC, Grout ME, Isabella CR, Tully HM, Doherty D, Bachmann-Gagescu R. 2018. Interpreting the clinical significance of combined variants in multiple recessive disease genes: systematic investigation of Joubert syndrome yields little support for oligogenicity. *Genetics in medicine : official journal of the American College of Medical Genetics* 20(2):223-233.
- Platis CM, Kachko L, Trabikina E, Simhi E, Bahar M, Katz J. 2006. Postoperative respiratory complications in Joubert syndrome. *Paediatric anaesthesia* 16(7):799-800.
- Poretti A, Boltshauser E, Loenneker T, Valente EM, Brancati F, Il'yasov K, Huisman TA. 2007. Diffusion tensor imaging in Joubert syndrome. *AJNR American journal of neuroradiology* 28(10):1929-1933.

- Poretti A, Hausler M, von Moers A, Baumgartner B, Zerres K, Klein A, Aiello C, Moro F, Zanni G, Santorelli FM, Huisman TA, Weis J, Valente EM, Bertini E, Boltshauser E. 2014. Ataxia, intellectual disability, and ocular apraxia with cerebellar cysts: a new disease? *Cerebellum* 13(1):79-88.
- Poretti A, Snow J, Summers AC, Tekes A, Huisman T, Aygun N, Carson KA, Doherty D, Parisi MA, Toro C, Yildirimli D, Vemulapalli M, Mullikin JC, Cullinane AR, Vilboux T, Gahl WA, Gunay-Aygun M. 2017. Joubert syndrome: neuroimaging findings in 110 patients in correlation with cognitive function and genetic cause. *Journal of medical genetics* 54(8):521-529.
- Poretti A, Vitiello G, Hennekam RC, Arrigoni F, Bertini E, Borgatti R, Brancati F, D'Arrigo S, Faravelli F, Giordano L, Huisman TA, Iannicelli M, Kluger G, Kyllerman M, Landgren M, Lees MM, Pinelli L, Romaniello R, Scheer I, Schwarz CE, Spiegel R, Tibussek D, Valente EM, Boltshauser E. 2012. Delineation and diagnostic criteria of Oral-Facial-Digital Syndrome type VI. *Orphanet journal of rare diseases* 7:4.
- Putoux A, Thomas S, Coene KL, Davis EE, Alanay Y, Ogur G, Uz E, Buzas D, Gomes C, Patrier S, Bennett CL, Elkhartoufi N, Frison MH, Rigonnot L, Joye N, Pruvost S, Utine GE, Boduroglu K, Nitschke P, Fertitta L, Thauvin-Robinet C, Munnich A, Cormier-Daire V, Hennekam R, Colin E, Akarsu NA, Bole-Feysot C, Cagnard N, Schmitt A, Goudin N, Lyonnet S, Encha-Razavi F, Siffroi JP, Winey M, Katsanis N, Gonzales M, Vekemans M, Beales PL, Attie-Bitach T. 2011. KIF7 mutations cause fetal hydrolethrus and acrocallosal syndromes. *Nature genetics* 43(6):601-606.
- Ramsbottom SA, Molinari E, Srivastava S, Silberman F, Henry C, Alkanderi S, Devlin LA, White K, Steel DH, Saunier S, Miles CG, Sayer JA. 2018. Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model. *Proceedings of the National Academy of Sciences of the United States of America* 115(49):12489-12494.
- Reiter JF, Leroux MR. 2017. Genes and molecular pathways underpinning ciliopathies. *Nature reviews Molecular cell biology* 18(9):533-547.
- Romani M, Micalizzi A, Kraoua I, Dotti MT, Cavallin M, Sztriha L, Ruta R, Mancini F, Mazza T, Castellana S, Hanene B, Carluccio MA, Darra F, Mate A, Zimmermann A, Gouider-Khouja N, Valente EM. 2014. Mutations in B9D1 and MKS1 cause mild Joubert syndrome: expanding the genetic overlap with the lethal ciliopathy Meckel syndrome. *Orphanet journal of rare diseases* 9:72.
- Romani M, Micalizzi A, Valente EM. 2013. Joubert syndrome: congenital cerebellar ataxia with the molar tooth. *The Lancet Neurology* 12(9):894-905.
- Roosing S, Romani M, Isrie M, Rosti RO, Micalizzi A, Musaev D, Mazza T, Al-Gazali L, Altunoglu U, Boltshauser E, D'Arrigo S, De Keersmaecker B, Kayserili H, Brandenberger S, Kraoua I, Mark PR, McKanna T, Van Keirsbilck J, Moerman P, Poretti A, Puri R, Van Esch H, Gleeson JG, Valente EM. 2016. Mutations in CEP120 cause Joubert syndrome as well as complex ciliopathy phenotypes. *Journal of medical genetics* 53(9):608-615.
- Ruggenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G. 2016. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. *Clinical journal of the American Society of Nephrology : CJASN* 11(5):785-794.
- Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. 2017. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. *Lancet* 390(10097):849-860.
- Saleem SN, Zaki MS. 2010. Role of MR imaging in prenatal diagnosis of pregnancies at risk for Joubert syndrome and related cerebellar disorders. *AJNR American journal of neuroradiology* 31(3):424-429.
- Sanders AA, de Vrieze E, Alazami AM, Alzahrani F, Malarkey EB, Soroush N, Tebbe L, Kuhns S, van Dam TJ, Alhashem A, Tabarki B, Lu Q, Lambacher NJ, Kennedy JE, Bowie RV, Hetterschijt L, van Beersum S, van Reeuwijk J, Boldt K, Kremer H, Kesterson RA, Monies D, Abouelhoda M, Roepman R, Huynen MH,

- Ueffing M, Russell RB, Wolfrum U, Yoder BK, van Wijk E, Alkuraya FS, Blacque OE. 2015. KIAA0556 is a novel ciliary basal body component mutated in Joubert syndrome. *Genome biology* 16:293.
- Sang L, Miller JJ, Corbit KC, Giles RH, Brauer MJ, Otto EA, Baye LM, Wen X, Scales SJ, Kwong M, Huntzicker EG, Sfakianos MK, Sandoval W, Bazan JF, Kulkarni P, Garcia-Gonzalo FR, Seol AD, O'Toole JF, Held S, Reutter HM, Lane WS, Rafiq MA, Noor A, Ansar M, Devi AR, Sheffield VC, Slusarski DC, Vincent JB, Doherty DA, Hildebrandt F, Reiter JF, Jackson PK. 2011. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. *Cell* 145(4):513-528.
- Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA, Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A, Leroux MR, Hildebrandt F. 2006. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. *Nat Genet* 38(6):674-681.
- Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, Munoz A. 2012. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. *Kidney international* 82(4):445-453.
- Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wuthrich RP. 2010. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. *The New England journal of medicine* 363(9):820-829.
- Shaheen R, Jiang N, Alzahrani F, Ewida N, Al-Sheddi T, Alobeid E, Musaev D, Stanley V, Hashem M, Ibrahim N, Abdulwahab F, Alshenqiti A, Sonmez FM, Saqati N, Alzaidan H, Al-Qattan MM, Al-Mohanna F, Gleeson JG, Alkuraya FS. 2019. Bi-allelic Mutations in FAM149B1 Cause Abnormal Primary Cilium and a Range of Ciliopathy Phenotypes in Humans. *American journal of human genetics* 104(4):731-737.
- Shaheen R, Schmidts M, Fageih E, Hashem A, Lausch E, Holder I, Superti-Furga A, Mitchison HM, Almoisheer A, Alamro R, Alshiddi T, Alzahrani F, Beales PL, Alkuraya FS. 2015. A founder CEP120 mutation in Jeune asphyxiating thoracic dystrophy expands the role of centriolar proteins in skeletal ciliopathies. *Human molecular genetics* 24(5):1410-1419.
- Shaheen R, Shamseldin HE, Loucks CM, Seidahmed MZ, Ansari S, Ibrahim Khalil M, Al-Yacoub N, Davis EE, Mola NA, Szymanska K, Herridge W, Chudley AE, Chodirker BN, Schwartzentruber J, Majewski J, Katsanis N, Poizat C, Johnson CA, Parboosingh J, Boycott KM, Innes AM, Alkuraya FS. 2014. Mutations in CSPP1, encoding a core centrosomal protein, cause a range of ciliopathy phenotypes in humans. *American journal of human genetics* 94(1):73-79.
- Shaheen R, Szymanska K, Basu B, Patel N, Ewida N, Fageih E, Al Hashem A, Derar N, Alsharif H, Aldahmesh MA, Alazami AM, Hashem M, Ibrahim N, Abdulwahab FM, Sonbul R, Alkuraya H, Alnemer M, Al Tala S, Al-Husain M, Morsy H, Seidahmed MZ, Meriki N, Al-Owain M, AlShahwan S, Tabarki B, Salih MA, Faquih T, El-Kalioby M, Ueffing M, Boldt K, Logan CV, Parry DA, Al Tassan N, Monies D, Megarbane A, Abouelhoda M, Halees A, Johnson CA, Alkuraya FS. 2016. Characterizing the morbid genome of ciliopathies. *Genome biology* 17(1):242.
- Sriganesh K, Smita V, Aravind HS. 2010. Clonidine as a sole sedative agent for MRI study in a child with Joubert syndrome. *Paediatric anaesthesia* 20(6):578-579.
- Sriganesh K, Vinay B, Jena S, Sudhir V, Saini J, Umamaheswara Rao GS. 2014. Anesthetic management of patients with Joubert syndrome: a retrospective analysis of a single-institutional case series. *Paediatric anaesthesia* 24(11):1180-1184.
- Srour M, Hamdan FF, McKnight D, Davis E, Mandel H, Schwartzentruber J, Martin B, Patry L, Nassif C, Dionne-Laporte A, Ospina LH, Lemyre E, Massicotte C, Laframboise R, Maranda B, Labuda D, Decarie JC, Rypens F, Goldsher D, Fallet-Bianco C, Soucy JF, Laberge AM, Maftei C, Boycott K, Brais B, Boucher RM, Rouleau GA, Katsanis N, Majewski J, Elpeleg O, Kukulich MK, Shalev S, Michaud JL. 2015. Joubert Syndrome in French Canadians and Identification of Mutations in CEP104. *American journal of human genetics* 97(5):744-753.
- Srour M, Hamdan FF, Schwartzentruber JA, Patry L, Ospina LH, Shevell MI, Desilets V, Dobrzaniecka S, Mathonnet G, Lemyre E, Massicotte C, Labuda D, Amrom D, Andermann E, Sebire G, Maranda B,

- Rouleau GA, Majewski J, Michaud JL. 2012a. Mutations in TMEM231 cause Joubert syndrome in French Canadians. *Journal of medical genetics* 49(10):636-641.
- Srour M, Schwartzentruber J, Hamdan FF, Ospina LH, Patry L, Labuda D, Massicotte C, Dobrzeniecka S, Capochichi JM, Papillon-Cavanagh S, Samuels ME, Boycott KM, Shevell MI, Laframboise R, Desilets V, Maranda B, Rouleau GA, Majewski J, Michaud JL. 2012b. Mutations in C5ORF42 cause Joubert syndrome in the French Canadian population. *American journal of human genetics* 90(4):693-700.
- Stephen J, Vilboux T, Mian L, Kuptanon C, Sinclair CM, Yildirimli D, Maynard DM, Bryant J, Fischer R, Vemulapalli M, Mullikin JC, Huizing M, Gahl WA, Malicdan MCV, Gunay-Aygun M. 2017. Mutations in KIAA0753 cause Joubert syndrome associated with growth hormone deficiency. *Human genetics* 136(4):399-408.
- Stephen LA, Tawamie H, Davis GM, Tebbe L, Nurnberg P, Nurnberg G, Thiele H, Thoenes M, Boltshauser E, Uebe S, Rompel O, Reis A, Ekici AB, McTeir L, Fraser AM, Hall EA, Mill P, Daudet N, Cross C, Wolfrum U, Jamra RA, Davey MG, Bolz HJ. 2015. TALPID3 controls centrosome and cell polarity and the human ortholog KIAA0586 is mutated in Joubert syndrome (JBTS23). *eLife* 4.
- Strongin A, Heller T, Doherty D, Glass IA, Parisi MA, Bryant J, Choyke P, Turkbey B, Daryanani K, Yildirimli D, Vemulapalli M, Mullikin JC, Malicdan MC, Vilboux T, Gahl WA, Gunay-Aygun M. 2018. Characteristics of Liver Disease in 100 Individuals With Joubert Syndrome Prospectively Evaluated at a Single Center. *Journal of pediatric gastroenterology and nutrition* 66(3):428-435.
- Sturm V, Leiba H, Menke MN, Valente EM, Poretti A, Landau K, Boltshauser E. 2010. Ophthalmological findings in Joubert syndrome. *Eye (Lond)* 24(2):222-225.
- Summers AC, Snow J, Wiggs E, Liu AG, Toro C, Poretti A, Zein WM, Brooks BP, Parisi MA, Inati S, Doherty D, Vemulapalli M, Mullikin JC, Vilboux T, Gahl WA, Gunay-Aygun M. 2017. Neuropsychological phenotypes of 76 individuals with Joubert syndrome evaluated at a single center. *American journal of medical genetics Part A*.
- Thauvin-Robinet C, Lee JS, Lopez E, Herranz-Perez V, Shida T, Franco B, Jegu L, Ye F, Pasquier L, Loget P, Gigot N, Aral B, Lopes CA, St-Onge J, Bruel AL, Thevenon J, Gonzalez-Granero S, Alby C, Munnich A, Vekemans M, Huet F, Fry AM, Saunier S, Riviere JB, Attie-Bitach T, Garcia-Verdugo JM, Faivre L, Megarbane A, Nachury MV. 2014. The oral-facial-digital syndrome gene C2CD3 encodes a positive regulator of centriole elongation. *Nature genetics* 46(8):905-911.
- Thomas S, Legendre M, Saunier S, Bessieres B, Alby C, Bonniere M, Toutain A, Loeuillet L, Szymanska K, Jossic F, Gaillard D, Yacoubi MT, Mougou-Zerelli S, David A, Barthez MA, Ville Y, Bole-Feynot C, Nitschke P, Lyonnet S, Munnich A, Johnson CA, Encha-Razavi F, Cormier-Daire V, Thauvin-Robinet C, Vekemans M, Attie-Bitach T. 2012. TCTN3 mutations cause Mohr-Majewski syndrome. *American journal of human genetics* 91(2):372-378.
- Thomas S, Wright KJ, Le Corre S, Micalizzi A, Romani M, Abhyankar A, Saada J, Perrault I, Amiel J, Litzler J, Filhol E, Elkhartoufi N, Kwong M, Casanova JL, Boddaert N, Baehr W, Lyonnet S, Munnich A, Burglen L, Chassaing N, Encha-Ravazi F, Vekemans M, Gleeson JG, Valente EM, Jackson PK, Drummond IA, Saunier S, Attie-Bitach T. 2014. A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium. *Human mutation* 35(1):137-146.
- Toriyama M, Lee C, Taylor SP, Duran I, Cohn DH, Bruel AL, Tabler JM, Drew K, Kelly MR, Kim S, Park TJ, Braun DA, Pierquin G, Biver A, Wagner K, Malfroot A, Panigrahi I, Franco B, Al-Lami HA, Yeung Y, Choi YJ, Duffourd Y, Faivre L, Riviere JB, Chen J, Liu KJ, Marcotte EM, Hildebrandt F, Thauvin-Robinet C, Krakow D, Jackson PK, Wallingford JB. 2016. The ciliopathy-associated CPLANE proteins direct basal body recruitment of intraflagellar transport machinery. *Nature genetics* 48(6):648-656.
- Tuz K, Bachmann-Gagescu R, O'Day DR, Hua K, Isabella CR, Phelps IG, Stolarski AE, O'Roak BJ, Dempsey JC, Lourenco C, Alswaid A, Bonnemann CG, Medne L, Nampoothiri S, Stark Z, Leventer RJ, Topcu M, Cansu A, Jagadeesh S, Done S, Ishak GE, Glass IA, Shendure J, Neuhauss SC, Haldeman-Englert CR, Doherty D, Ferland RJ. 2014. Mutations in CSPP1 cause primary cilia abnormalities and Joubert syndrome with or without Jeune asphyxiating thoracic dystrophy. *American journal of human genetics* 94(1):62-72.
- Valente EM, Logan CV, Mougou-Zerelli S, Lee JH, Silhavy JL, Brancati F, Iannicelli M, Travaglini L, Romani S, Illi B, Adams M, Szymanska K, Mazzotta A, Lee JE, Tolentino JC, Swistun D, Salpietro CD, Fede C, Gabriel

- S, Russ C, Cibulskis K, Sougnez C, Hildebrandt F, Otto EA, Held S, Diplas BH, Davis EE, Mikula M, Strom CM, Ben-Zeev B, Lev D, Sagie TL, Michelson M, Yaron Y, Krause A, Boltshauser E, Elkhartoufi N, Roume J, Shalev S, Munnich A, Saunier S, Inglehearn C, Saad A, Alkindy A, Thomas S, Vekemans M, Dallapiccola B, Katsanis N, Johnson CA, Attie-Bitach T, Gleeson JG. 2010. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. *Nature genetics* 42(7):619-625.
- Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, Lancaster MA, Boltshauser E, Boccone L, Al-Gazali L, Fazzi E, Signorini S, Louie CM, Bellacchio E, Bertini E, Dallapiccola B, Gleeson JG. 2006. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nature genetics* 38(6):623-625.
- Van De Weghe JC, Rusterholz TDS, Latour B, Grout ME, Aldinger KA, Shaheen R, Dempsey JC, Maddirevula S, Cheng YH, Phelps IG, Gesemann M, Goel H, Birk OS, Alanzi T, Rawashdeh R, Khan AO, Bamshad MJ, Nickerson DA, Neuhauss SCF, Dobyns WB, Alkuraya FS, Roepman R, Bachmann-Gagescu R, Doherty D. 2017. Mutations in ARMC9, which Encodes a Basal Body Protein, Cause Joubert Syndrome in Humans and Ciliopathy Phenotypes in Zebrafish. *American journal of human genetics* 101(1):23-36.
- Vilboux T, Doherty DA, Glass IA, Parisi MA, Phelps IG, Cullinane AR, Zein W, Brooks BP, Heller T, Soldatos A, Oden NL, Yildirimli D, Vemulapalli M, Mullikin JC, Nisc Comparative Sequencing P, Malicdan MCV, Gahl WA, Gunay-Aygun M. 2017a. Molecular genetic findings and clinical correlations in 100 patients with Joubert syndrome and related disorders prospectively evaluated at a single center. *Genetics in medicine : official journal of the American College of Medical Genetics* 19(8):875-882.
- Vilboux T, Malicdan MC, Roney JC, Cullinane AR, Stephen J, Yildirimli D, Bryant J, Fischer R, Vemulapalli M, Mullikin JC, Steinbach PJ, Gahl WA, Gunay-Aygun M. 2017b. CELSR2, encoding a planar cell polarity protein, is a putative gene in Joubert syndrome with cortical heterotopia, microphthalmia, and growth hormone deficiency. *American journal of medical genetics Part A* 173(3):661-666.
- Vodopich DJ, Gordon GJ. 2004. Anesthetic management in Joubert syndrome. *Paediatric anaesthesia* 14(10):871-873.
- Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU. 2010. Everolimus in patients with autosomal dominant polycystic kidney disease. *The New England journal of medicine* 363(9):830-840.
- Weiss AH, Doherty D, Parisi M, Shaw D, Glass I, Phillips JO. 2009. Eye movement abnormalities in Joubert syndrome. *Investigative ophthalmology & visual science* 50(10):4669-4677.
- Wheway G, Schmidts M, Mans DA, Szymanska K, Nguyen TT, Racher H, Phelps IG, Toedt G, Kennedy J, Wunderlich KA, Sorusch N, Abdelhamed ZA, Natarajan S, Herridge W, van Reeuwijk J, Horn N, Boldt K, Parry DA, Letteboer SJF, Roosing S, Adams M, Bell SM, Bond J, Higgins J, Morrison EE, Tomlinson DC, Slaats GG, van Dam TJP, Huang L, Kessler K, Giessl A, Logan CV, Boyle EA, Shendure J, Anazi S, Aldahmesh M, Al Hazzaa S, Hegele RA, Ober C, Frosk P, Mhanni AA, Chodirker BN, Chudley AE, Lamont R, Bernier FP, Beaulieu CL, Gordon P, Pon RT, Donahue C, Barkovich AJ, Wolf L, Toomes C, Thiel CT, Boycott KM, McKibbin M, Inglehearn CF, Stewart F, Omran H, Huynen MA, Sergouniotis PI, Alkuraya FS, Parboosingh JS, Innes AM, Willoughby CE, Giles RH, Webster AR, Ueffing M, Blacque O, Gleeson JG, Wolfrum U, Beales PL, Gibson T, Doherty D, Mitchison HM, Roepman R, Johnson CA. 2015. An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. *Nature cell biology* 17(8):1074-1087.
- Widjaja E, Blaser S, Raybaud C. 2006. Diffusion tensor imaging of midline posterior fossa malformations. *Pediatric radiology* 36(6):510-517.
- Witmans M, Young R. 2011. Update on pediatric sleep-disordered breathing. *Pediatric clinics of North America* 58(3):571-589.
- Wolfe L, Lakadamyali H, Mutlu GM. 2010. Joubert syndrome associated with severe central sleep apnea. *Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine* 6(4):384-388.